

Increased circulating myeloid-derived suppressor cells
stage, metastatic tumor burden, and doxorubicinâ€“cyc

Cancer Immunology, Immunotherapy

58, 49-59

DOI: [10.1007/s00262-008-0523-4](https://doi.org/10.1007/s00262-008-0523-4)

Citation Report

#	ARTICLE	IF	CITATIONS
1	The role of myeloid cells in the promotion of tumour angiogenesis. <i>Nature Reviews Cancer</i> , 2008, 8, 618-631.	12.8	1,404
2	Proinflammatory S100 Proteins Regulate the Accumulation of Myeloid-Derived Suppressor Cells. <i>Journal of Immunology</i> , 2008, 181, 4666-4675.	0.4	634
3	Subsets of Myeloid-Derived Suppressor Cells in Tumor-Bearing Mice. <i>Journal of Immunology</i> , 2008, 181, 5791-5802.	0.4	1,447
4	Gene Expression Profiles in Peripheral Blood Mononuclear Cells Can Distinguish Patients with Non-Small Cell Lung Cancer from Patients with Nonmalignant Lung Disease. <i>Cancer Research</i> , 2009, 69, 9202-9210.	0.4	140
5	Modulating the Expression of IFN Regulatory Factor 8 Alters the Protumorigenic Behavior of CD11b+Gr-1+ Myeloid Cells. <i>Journal of Immunology</i> , 2009, 183, 117-128.	0.4	39
6	Inflammation: A driving force speeds cancer metastasis. <i>Cell Cycle</i> , 2009, 8, 3267-3273.	1.3	289
7	Tumor and iatrogenic regulation of myeloid precursors and their potential to limit immune therapy. <i>Immunotherapy</i> , 2009, 1, 5-9.	1.0	0
8	The Liver Is a Site for Tumor-Induced Myeloid-Derived Suppressor Cell Accumulation and Immunosuppression. <i>Cancer Research</i> , 2009, 69, 5514-5521.	0.4	166
9	Cytokines and angiogenic factors in patients with metastatic renal cell carcinoma treated with interferon- α : association of pretreatment serum levels with survival. <i>Annals of Oncology</i> , 2009, 20, 1682-1687.	0.6	30
10	Effect of Granulocyte/Macrophage Colony-Stimulating Factor on Vaccination with an Allogeneic Whole-Cell Melanoma Vaccine. <i>Clinical Cancer Research</i> , 2009, 15, 7029-7035.	3.2	82
11	Adoptive transfer of HER2/neu-specific T cells expanded with alternating gamma chain cytokines mediate tumor regression when combined with the depletion of myeloid-derived suppressor cells. <i>Cancer Immunology, Immunotherapy</i> , 2009, 58, 941-953.	2.0	51
12	Myeloid-derived suppressor cells as regulators of the immune system. <i>Nature Reviews Immunology</i> , 2009, 9, 162-174.	10.6	5,655
13	Molecular mechanisms mediating oxidative stress-induced T-cell suppression in cancer. <i>Advances in Enzyme Regulation</i> , 2009, 49, 107-112.	2.9	9
14	Tumor and stromal pathways mediating refractoriness/resistance to anti-angiogenic therapies. <i>Trends in Pharmacological Sciences</i> , 2009, 30, 624-630.	4.0	137
15	IL4R α + Myeloid-Derived Suppressor Cell Expansion in Cancer Patients. <i>Journal of Immunology</i> , 2009, 182, 6562-6568.	0.4	287
16	Mechanism Regulating Reactive Oxygen Species in Tumor-Induced Myeloid-Derived Suppressor Cells. <i>Journal of Immunology</i> , 2009, 182, 5693-5701.	0.4	655
17	Inflammation enhances myeloid-derived suppressor cell cross-talk by signaling through Toll-like receptor 4. <i>Journal of Leukocyte Biology</i> , 2009, 85, 996-1004.	1.5	230
18	Chronic inflammation, the tumor microenvironment and carcinogenesis. <i>Cell Cycle</i> , 2009, 8, 2005-2013.	1.3	222

#	ARTICLE	IF	CITATIONS
19	Myeloid-Derived Suppressor Cells: Linking Inflammation and Cancer. <i>Journal of Immunology</i> , 2009, 182, 4499-4506.	0.4	1,524
20	Administration of Cyclophosphamide Changes the Immune Profile of Tumor-bearing Mice. <i>Journal of Immunotherapy</i> , 2010, 33, 53-59.	1.2	42
21	Myeloid-Derived Suppressor Cells in Human Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2010, 16, 348-353.	1.0	203
22	Chemoimmunotherapy. <i>Cancer Journal (Sudbury, Mass)</i> , 2010, 16, 295-303.	1.0	91
23	A Novel Breast/Ovarian Cancer Peptide Vaccine Platform That Promotes Specific Type-1 but not Treg/Tr1-type Responses. <i>Journal of Immunotherapy</i> , 2010, 33, 250-261.	1.2	30
24	Epithelialâ€“Mesenchymal Transition in Development and Diseases. , 2010, , 187-211.		3
26	Myeloid-derived suppressor cells in mammary tumor progression in FVB Neu transgenic mice. <i>Cancer Immunology, Immunotherapy</i> , 2010, 59, 47-62.	2.0	46
27	Dendritic cell recovery post-lymphodepletion: a potential mechanism for anti-cancer adoptive T cell therapy and vaccination. <i>Cancer Immunology, Immunotherapy</i> , 2010, 59, 341-353.	2.0	36
28	The Tumor Microenvironment in Colorectal Carcinogenesis. <i>Cancer Microenvironment</i> , 2010, 3, 149-166.	3.1	179
29	GM-CSF is one of the main breast tumor-derived soluble factors involved in the differentiation of CD11b-Gr1- bone marrow progenitor cells into myeloid-derived suppressor cells. <i>Breast Cancer Research and Treatment</i> , 2010, 123, 39-49.	1.1	179
30	Breast cancer cell CD200 expression regulates immune response to EMT6 tumor cells in mice. <i>Breast Cancer Research and Treatment</i> , 2010, 123, 405-415.	1.1	53
31	The potential use of Toll-like receptor agonists to restore the dysfunctional immunity induced by hepatitis C virus. <i>Cellular Immunology</i> , 2010, 262, 96-104.	1.4	10
32	Myeloidâ€“derived suppressor cells in parasitic infections. <i>European Journal of Immunology</i> , 2010, 40, 2976-2985.	1.6	107
33	Myeloid-derived suppressor cell heterogeneity and subset definition. <i>Current Opinion in Immunology</i> , 2010, 22, 238-244.	2.4	579
34	Development and Function of Myeloid-Derived Suppressor Cells Generated From Mouse Embryonic and Hematopoietic Stem Cells. <i>Stem Cells</i> , 2010, 28, 620-632.	1.4	134
35	Increased Level of both CD4+FOXP3+ Regulatory T Cells and CD14+HLA-DRâˆ“/low Myeloid-Derived Suppressor Cells and Decreased Level of Dendritic Cells in Patients with Multiple Myeloma. <i>Scandinavian Journal of Immunology</i> , 2010, 72, 540-547.	1.3	200
36	Targeting the tumour vasculature: insights from physiological angiogenesis. <i>Nature Reviews Cancer</i> , 2010, 10, 505-514.	12.8	648
37	Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells. <i>Journal of Clinical Investigation</i> , 2010, 120, 457-71.	3.9	761

#	ARTICLE	IF	CITATIONS
38	A Novel Chemoimmunomodulating Property of Docetaxel: Suppression of Myeloid-Derived Suppressor Cells in Tumor Bearers. <i>Clinical Cancer Research</i> , 2010, 16, 4583-4594.	3.2	439
39	Immature Immunosuppressive CD14+HLA-DR ^{hi} /low Cells in Melanoma Patients Are Stat3 ^{hi} and Overexpress CD80, CD83, and DC-Sign. <i>Cancer Research</i> , 2010, 70, 4335-4345.	0.4	366
40	HIF-1 α regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment. <i>Journal of Experimental Medicine</i> , 2010, 207, 2439-2453.	4.2	966
41	The Inflammasome Component Nlrp3 Impairs Antitumor Vaccine by Enhancing the Accumulation of Tumor-Associated Myeloid-Derived Suppressor Cells. <i>Cancer Research</i> , 2010, 70, 10161-10169.	0.4	139
42	T regulatory cells in cancer: recent advances and therapeutic potential. <i>Expert Opinion on Biological Therapy</i> , 2010, 10, 1573-1586.	1.4	94
43	Myeloid derived suppressor cells and their role in tolerance induction in cancer. <i>Journal of Dermatological Science</i> , 2010, 59, 1-6.	1.0	75
44	Myeloid-derived suppressor cells: Natural regulators for transplant tolerance. <i>Human Immunology</i> , 2010, 71, 1061-1066.	1.2	55
45	Neutrophils: Cinderella of innate immune system. <i>International Immunopharmacology</i> , 2010, 10, 1325-1334.	1.7	343
46	Pathways mediating VEGF-independent tumor angiogenesis. <i>Cytokine and Growth Factor Reviews</i> , 2010, 21, 21-26.	3.2	273
47	Dendritic cell vaccine in addition to FOLFIRI regimen improve antitumor effects through the inhibition of immunosuppressive cells in murine colorectal cancer model. <i>Vaccine</i> , 2010, 28, 7787-7796.	1.7	18
48	Association of Blood Monocyte and Lymphocyte Count and Disease-Free Interval in Dogs with Osteosarcoma. <i>Journal of Veterinary Internal Medicine</i> , 2010, 24, 1439-1444.	0.6	57
49	Characterization of Cytokine-Induced Myeloid-Derived Suppressor Cells from Normal Human Peripheral Blood Mononuclear Cells. <i>Journal of Immunology</i> , 2010, 185, 2273-2284.	0.4	533
50	Tumour-Induced Immune Suppression by Myeloid Cells. , 2011, , 49-62.		0
51	Conjugate (MTC-220) of Muramyl Dipeptide Analogue and Paclitaxel Prevents Both Tumor Growth and Metastasis in Mice. <i>Journal of Medicinal Chemistry</i> , 2011, 54, 2767-2777.	2.9	32
52	Specific peripheral miRNA profiles for distinguishing lung cancer from COPD. <i>Lung Cancer</i> , 2011, 74, 41-47.	0.9	96
53	Intrinsic modulation of lymphocyte function by stromal cell network: advance in therapeutic targeting of cancer. <i>Immunotherapy</i> , 2011, 3, 1253-1264.	1.0	12
54	Myeloid-derived suppressor cells in the peripheral blood of cancer patients contain a subset of immature neutrophils with impaired migratory properties. <i>Journal of Leukocyte Biology</i> , 2010, 89, 311-317.	1.5	274
55	Myeloid derived suppressor cells in human diseases. <i>International Immunopharmacology</i> , 2011, 11, 802-807.	1.7	374

#	ARTICLE	IF	CITATIONS
56	Antitumor vaccination by Newcastle Disease Virus Hemagglutininâ€“Neuraminidase plasmid DNA application: Changes in tumor microenvironment and activation of innate anti-tumor immunity. <i>Vaccine</i> , 2011, 29, 1185-1193.	1.7	23
57	Developmental and Pathological Angiogenesis. <i>Annual Review of Cell and Developmental Biology</i> , 2011, 27, 563-584.	4.0	620
58	Exosomes and Cancer: A Newly Described Pathway of Immune Suppression. <i>Clinical Cancer Research</i> , 2011, 17, 959-964.	3.2	247
59	Myeloid-derived suppressor cells (MDSC): Another player in the orchestra. <i>Immunologia (Barcelona)</i> , 2011, 15, 1-14.	0.1	8
60	Novel CCL21-Vault Nanocapsule Intratumoral Delivery Inhibits Lung Cancer Growth. <i>PLoS ONE</i> , 2011, 6, e18758.	1.1	93
61	Enhanced T-cell-independent Antitumor Effect of Cyclophosphamide Combined With Anti-CD40 mAb and CpG in Mice. <i>Journal of Immunotherapy</i> , 2011, 34, 76-84.	1.2	19
62	Myeloid-Derived Suppressor Cells: General Characteristics and Relevance to Clinical Management of Pancreatic Cancer. <i>Current Cancer Drug Targets</i> , 2011, 11, 734-751.	0.8	97
63	Myeloid-derived suppressor cells â€“ their role in haematological malignancies and other cancers and possible implications for therapy. <i>British Journal of Haematology</i> , 2011, 153, 557-567.	1.2	49
64	The role of interleukin-12 on modulating myeloid-derived suppressor cells, increasing overall survival and reducing metastasis. <i>Immunology</i> , 2011, 133, 221-238.	2.0	101
65	Myeloid-derived suppressor cells: a double-edged sword?. <i>International Journal of Experimental Pathology</i> , 2011, 92, 73-78.	0.6	31
66	Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication. <i>Immunological Reviews</i> , 2011, 241, 104-118.	2.8	229
67	Areca nut extracts enhance the development of CD11b+Gr-1+ cells with the characteristics of myeloid-derived suppressor cells in antigen-stimulated mice. <i>Journal of Oral Pathology and Medicine</i> , 2011, 40, 769-777.	1.4	10
68	Cancer-testis antigen, BORIS based vaccine delivered by dendritic cells is extremely effective against a very aggressive and highly metastatic mouse mammary carcinoma. <i>Cellular Immunology</i> , 2011, 270, 188-197.	1.4	30
69	A human promyelocytic-like population is responsible for the immune suppression mediated by myeloid-derived suppressor cells. <i>Blood</i> , 2011, 118, 2254-2265.	0.6	328
70	Role of CD200 expression in regulation of metastasis of EMT6 tumor cells in mice. <i>Breast Cancer Research and Treatment</i> , 2011, 130, 49-60.	1.1	35
71	Myeloid cell diversification and complexity: an old concept with new turns in oncology. <i>Cancer and Metastasis Reviews</i> , 2011, 30, 27-43.	2.7	36
72	Improving cancer immunotherapy by targeting tumor-induced immune suppression. <i>Cancer and Metastasis Reviews</i> , 2011, 30, 125-140.	2.7	127
73	Camouflage and sabotage: tumor escape from the immune system. <i>Cancer Immunology, Immunotherapy</i> , 2011, 60, 1161-1171.	2.0	150

#	ARTICLE	IF	CITATIONS
74	Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13. <i>Cancer Immunology, Immunotherapy</i> , 2011, 60, 1419-1430.	2.0	506
75	Distinct myeloid suppressor cell subsets correlate with plasma IL-6 and IL-10 and reduced interferon-alpha signaling in CD4+ T cells from patients with GI malignancy. <i>Cancer Immunology, Immunotherapy</i> , 2011, 60, 1269-1279.	2.0	134
76	Contribution of the immune system to the chemotherapeutic response. <i>Seminars in Immunopathology</i> , 2011, 33, 353-367.	2.8	30
77	Targeting myeloid regulatory cells in cancer by chemotherapeutic agents. <i>Immunologic Research</i> , 2011, 50, 276-285.	1.3	36
78	The Immune Microenvironment of Myeloma. <i>Cancer Microenvironment</i> , 2011, 4, 313-323.	3.1	44
79	Functional characterization of human Cd33+ And Cd11b+ myeloid-derived suppressor cell subsets induced from peripheral blood mononuclear cells co-cultured with a diverse set of human tumor cell lines. <i>Journal of Translational Medicine</i> , 2011, 9, 90.	1.8	186
80	Cytotoxic immunotherapy strategies for cancer: Mechanisms and clinical development. <i>Journal of Cellular Biochemistry</i> , 2011, 112, 1969-1977.	1.2	64
81	Targeting immune suppressing myeloid-derived suppressor cells in oncology. <i>Critical Reviews in Oncology/Hematology</i> , 2011, 77, 12-19.	2.0	134
82	Potential targets for pancreatic cancer immunotherapeutics. <i>Immunotherapy</i> , 2011, 3, 517-537.	1.0	57
83	Cross-talk between tumor and myeloid cells: how to tip the balance in favor of antitumor immunity. <i>Immunotherapy</i> , 2011, 3, 77-96.	1.0	25
84	Restoration of Antitumor Immunity Through Selective Inhibition of Myeloid Derived Suppressor Cells by Anticancer Therapies. <i>Current Molecular Medicine</i> , 2011, 11, 365-372.	0.6	64
85	Activated NKT Cells and NK Cells Render T Cells Resistant to Myeloid-Derived Suppressor Cells and Result in an Effective Adoptive Cellular Therapy against Breast Cancer in the FVBN202 Transgenic Mouse. <i>Journal of Immunology</i> , 2011, 187, 708-717.	0.4	39
86	A Novel Combination Immunotherapy for Cancer by IL-13R α 2-Targeted DNA Vaccine and Immunotoxin in Murine Tumor Models. <i>Journal of Immunology</i> , 2011, 187, 4935-4946.	0.4	30
87	Increased Circulating Immunosuppressive CD14 ⁺ HLA-DR ^{low} Cells Correlate with Clinical Cancer Stage and Pathological Grade in Patients with Bladder Carcinoma. <i>Journal of International Medical Research</i> , 2011, 39, 1381-1391.	0.4	61
88	TGF- β 2 Receptor II Loss Promotes Mammary Carcinoma Progression by Th17-Dependent Mechanisms. <i>Cancer Discovery</i> , 2011, 1, 430-441.	7.7	116
89	Identification of a myeloid-derived suppressor cell cystatin-like protein that inhibits metastasis. <i>FASEB Journal</i> , 2011, 25, 2626-2637.	0.2	28
90	Role of immune-regulatory cells in skin pathology. <i>Journal of Leukocyte Biology</i> , 2010, 89, 41-49.	1.5	11
91	The Consequence of Immune Suppressive Cells in the Use of Therapeutic Cancer Vaccines and Their Importance in Immune Monitoring. <i>Journal of Biomedicine and Biotechnology</i> , 2011, 2011, 1-8.	3.0	8

#	ARTICLE	IF	CITATIONS
92	Tolerance-Inducing Strategies in Islet Transplantation. <i>International Journal of Endocrinology</i> , 2012, 2012, 1-13.	0.6	15
93	Myeloid Cells Obtained from the Blood but Not from the Tumor Can Suppress T-cell Proliferation in Patients with Melanoma. <i>Clinical Cancer Research</i> , 2012, 18, 5212-5223.	3.2	87
94	Immunotherapy: Shifting the Balance of Cell-Mediated Immunity and Suppression in Human Prostate Cancer. <i>Cancers</i> , 2012, 4, 1333-1348.	1.7	4
95	Myeloid-Derived Suppressor Cells Participate in Preventing Graft Rejection. <i>Clinical and Developmental Immunology</i> , 2012, 2012, 1-6.	3.3	10
96	Nitric Oxide-Producing Myeloid-Derived Suppressor Cells Inhibit Vascular E-Selectin Expression in Human Squamous Cell Carcinomas. <i>Journal of Investigative Dermatology</i> , 2012, 132, 2642-2651.	0.3	63
97	Regional lymphatic immunity in melanoma. <i>Melanoma Research</i> , 2012, 22, 9-18.	0.6	18
98	IL-13 receptor-directed cancer vaccines and immunotherapy. <i>Immunotherapy</i> , 2012, 4, 443-451.	1.0	14
99	Evasion of COPD in smokers: at what price?. <i>European Respiratory Journal</i> , 2012, 39, 1298-1303.	3.1	17
100	ChemolmmunoModulation: Immune Regulation by the Antineoplastic Chemotherapeutic Agents. <i>Current Medicinal Chemistry</i> , 2012, 19, 1792-1803.	1.2	74
101	Cellular Therapy for Ovarian Cancer: Experimental and Clinical Perspectives. <i>Current Medicinal Chemistry</i> , 2012, 19, 3787-3793.	1.2	7
102	Depletion of phagocytic myeloid cells triggers spontaneous T cell- and NK cell-dependent antitumor activity. <i>Oncolmmunology</i> , 2012, 1, 1248-1257.	2.1	8
103	Harnessing DNA-induced immune responses for improving cancer vaccines. <i>Human Vaccines and Immunotherapeutics</i> , 2012, 8, 1682-1693.	1.4	26
104	Cancer immunotherapy. <i>Oncolmmunology</i> , 2012, 1, 201-204.	2.1	8
105	Functional Changes in Myeloid-Derived Suppressor Cells (MDSCs) during Tumor Growth: FKBP51 Contributes to the Regulation of the Immunosuppressive Function of MDSCs. <i>Journal of Immunology</i> , 2012, 188, 4226-4234.	0.4	44
106	The Microenvironmental Effect in the Progression, Metastasis, and Dormancy of Breast Cancer: A Model System within Bone Marrow. <i>International Journal of Breast Cancer</i> , 2012, 2012, 1-7.	0.6	33
107	Immunotherapy of Cancer: Reprogramming Tumor-Immune Crosstalk. <i>Clinical and Developmental Immunology</i> , 2012, 2012, 1-8.	3.3	8
108	TGF-Beta: a Master Switch in Tumor Immunity. <i>Current Pharmaceutical Design</i> , 2012, 18, 4126-4134.	0.9	40
109	Circulating myeloid-derived suppressor cells are increased and correlate to immune suppression, inflammation and hypoproteinemia in patients with cancer. <i>Oncology Reports</i> , 2012, 28, 453-458.	1.2	107

#	ARTICLE	IF	CITATIONS
110	Renal transplant recipients have elevated frequencies of circulating myeloid-derived suppressor cells. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 402-410.	0.4	49
111	Interaction Between Invariant NKT Cells and Myeloid-derived Suppressor Cells in Cancer Patients. <i>Journal of Immunotherapy</i> , 2012, 35, 449-459.	1.2	32
112	Differing Patterns of Circulating Regulatory T Cells and Myeloid-derived Suppressor Cells in Metastatic Melanoma Patients Receiving Anti-CTLA4 Antibody and Interferon- γ or TLR-9 Agonist and GM-CSF With Peptide Vaccination. <i>Journal of Immunotherapy</i> , 2012, 35, 702-710.	1.2	63
113	Cyclophosphamide-induced Myeloid-derived Suppressor Cell Population Is Immunosuppressive But Not Identical to Myeloid-derived Suppressor Cells Induced By Growing TC-1 Tumors. <i>Journal of Immunotherapy</i> , 2012, 35, 374-384.	1.2	45
114	Myeloid-derived Suppressor Cells in Cancer Patients. <i>Journal of Immunotherapy</i> , 2012, 35, 107-115.	1.2	195
115	Metastatic melanoma patients treated with dendritic cell vaccination, Interleukin-2 and metronomic cyclophosphamide: results from a phase II trial. <i>Cancer Immunology, Immunotherapy</i> , 2012, 61, 1791-1804.	2.0	103
116	Tumor-Expressed Inducible Nitric Oxide Synthase Controls Induction of Functional Myeloid-Derived Suppressor Cells through Modulation of Vascular Endothelial Growth Factor Release. <i>Journal of Immunology</i> , 2012, 188, 5365-5376.	0.4	137
117	Blockade of Myeloid-Derived Suppressor Cells after Induction of Lymphopenia Improves Adoptive T Cell Therapy in a Murine Model of Melanoma. <i>Journal of Immunology</i> , 2012, 189, 5147-5154.	0.4	101
118	Coordinated regulation of myeloid cells by tumours. <i>Nature Reviews Immunology</i> , 2012, 12, 253-268.	10.6	3,002
119	Macrophage Migration Inhibitory Factor Promotes Tumor Growth and Metastasis by Inducing Myeloid-Derived Suppressor Cells in the Tumor Microenvironment. <i>Journal of Immunology</i> , 2012, 189, 5533-5540.	0.4	172
120	Pancreatic adenocarcinoma induces bone marrow mobilization of myeloid-derived suppressor cells which promote primary tumor growth. <i>Cancer Immunology, Immunotherapy</i> , 2012, 61, 1373-1385.	2.0	242
121	Further evidence for a role of tumor CD200 expression in breast cancer metastasis: decreased metastasis in CD200R1KO mice or using CD200-silenced EMT6. <i>Breast Cancer Research and Treatment</i> , 2012, 136, 117-127.	1.1	26
122	Subset characterization of myeloid-derived suppressor cells arising during induction of BM chimerism in mice. <i>Bone Marrow Transplantation</i> , 2012, 47, 985-992.	1.3	29
123	Natural suppressor cells; past, present and future. <i>Frontiers in Bioscience - Elite</i> , 2012, E4, 1237.	0.9	6
124	The secret ally: immunostimulation by anticancer drugs. <i>Nature Reviews Drug Discovery</i> , 2012, 11, 215-233.	21.5	591
125	Proangiogenic immature myeloid cells populate the human placenta and their presence correlates with placental and birthweight. <i>American Journal of Obstetrics and Gynecology</i> , 2012, 207, 141.e1-141.e5.	0.7	11
126	IFN- γ producing T cells contribute to the increase of myeloid derived suppressor cells in tumor-bearing mice after cyclophosphamide treatment. <i>International Immunopharmacology</i> , 2012, 12, 425-432.	1.7	14
127	Tumor regulation of myeloid-derived suppressor cell proliferation and trafficking. <i>International Immunopharmacology</i> , 2012, 13, 245-256.	1.7	35

#	ARTICLE	IF	CITATIONS
128	Kinetics of rebounding of lymphoid and myeloid cells in mouse peripheral blood, spleen and bone marrow after treatment with cyclophosphamide. <i>Cellular Immunology</i> , 2012, 276, 67-74.	1.4	34
129	On the armament and appearances of human myeloid-derived suppressor cells. <i>Clinical Immunology</i> , 2012, 144, 250-268.	1.4	168
130	Amino Acid Metabolism Related to Immune Tolerance by MDSCs. <i>International Reviews of Immunology</i> , 2012, 31, 177-183.	1.5	22
131	Identification of myeloid derived suppressor cells in the peripheral blood of tumor bearing dogs. <i>BMC Veterinary Research</i> , 2012, 8, 209.	0.7	35
132	Myeloid cells in tumor inflammation. <i>Vascular Cell</i> , 2012, 4, 14.	0.2	56
133	Highlights on Molecular Mechanisms of MDSC-Mediated Immune Suppression: Paving the Way for New Working Hypotheses. <i>Immunological Investigations</i> , 2012, 41, 722-737.	1.0	31
134	Exploitation of the propulsive force of chemotherapy for improving the response to cancer immunotherapy. <i>Molecular Oncology</i> , 2012, 6, 1-14.	2.1	48
135	Improving Radioresponse Through Modification of the Tumor Immunological Microenvironment. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2012, 27, 6-11.	0.7	9
136	Trial watch. <i>Oncolmmunology</i> , 2012, 1, 1323-1343.	2.1	203
137	Breast cancer immunobiology driving immunotherapy: vaccines and immune checkpoint blockade. <i>Expert Review of Anticancer Therapy</i> , 2012, 12, 1597-1611.	1.1	144
138	Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape. <i>Nature Medicine</i> , 2012, 18, 1224-1231.	15.2	406
139	Phenotypic Plasticity of MDSC in Cancers. <i>Immunological Investigations</i> , 2012, 41, 711-721.	1.0	20
140	Comparison of the cytotoxic response against ovarian cancer by immune effector cells isolated and expanded from normal donors and ovarian cancer patients. <i>Cytotherapy</i> , 2012, 14, 716-723.	0.3	6
142	Identification of Myeloid Derived Suppressor Cells in Dogs with Naturally Occurring Cancer. <i>PLoS ONE</i> , 2012, 7, e33274.	1.1	43
143	Characterization and clinical implications of myeloid-derived suppressor cells in head and neck cancer. <i>Journal of Japan Society of Immunology & Allergology in Otolaryngology</i> , 2012, 30, 271-278.	0.0	0
144	High Immune Response Rates and Decreased Frequencies of Regulatory T Cells in Metastatic Renal Cell Carcinoma Patients after Tumor Cell Vaccination. <i>Molecular Medicine</i> , 2012, 18, 1499-1508.	1.9	16
145	Regulatory Cells and Multiple Myeloma. , 2012, , .		1
146	Intratumoral Injection of CpG Oligonucleotides Induces the Differentiation and Reduces the Immunosuppressive Activity of Myeloid-Derived Suppressor Cells. <i>Journal of Immunology</i> , 2012, 188, 1592-1599.	0.4	216

#	ARTICLE	IF	CITATIONS
147	Strategies for the discovery and development of therapies for metastatic breast cancer. <i>Nature Reviews Drug Discovery</i> , 2012, 11, 479-497.	21.5	310
148	Neutrophils and granulocytic myeloid-derived suppressor cells: immunophenotyping, cell biology and clinical relevance in human oncology. <i>Cancer Immunology, Immunotherapy</i> , 2012, 61, 1155-1167.	2.0	340
149	Role of myeloid-derived suppressor cells in tumor immunotherapy. <i>Immunotherapy</i> , 2012, 4, 43-57.	1.0	31
150	Exosome removal as a therapeutic adjuvant in cancer. <i>Journal of Translational Medicine</i> , 2012, 10, 134.	1.8	329
151	Serum inhibits the immunosuppressive function of myeloid-derived suppressor cells isolated from 4T1 tumor-bearing mice. <i>Cancer Immunology, Immunotherapy</i> , 2012, 61, 643-654.	2.0	13
152	Myeloid-derived suppressor cells contribute to oral cancer progression in 4NQO-treated mice. <i>Oral Diseases</i> , 2012, 18, 67-73.	1.5	29
153	The glutathione disulfide mimetic NOV-002 inhibits cyclophosphamide-induced hematopoietic and immune suppression by reducing oxidative stress. <i>Free Radical Biology and Medicine</i> , 2012, 52, 1560-1568.	1.3	28
154	S100A9 a new marker for monocytic human myeloid-derived suppressor cells. <i>Immunology</i> , 2012, 136, 176-183.	2.0	176
155	New insights into chronic inflammation-induced immunosuppression. <i>Seminars in Cancer Biology</i> , 2012, 22, 307-318.	4.3	169
156	Myeloid-derived suppressor cell measurements in fresh and cryopreserved blood samples. <i>Journal of Immunological Methods</i> , 2012, 381, 14-22.	0.6	185
157	Immunosuppressive activity of CD ¹⁴ ⁺ HLA ^{DR} ⁺ cells in squamous cell carcinoma of the head and neck. <i>Cancer Science</i> , 2012, 103, 976-983.	1.7	96
158	Circulating and tumor-infiltrating myeloid cell subsets in patients with bladder cancer. <i>International Journal of Cancer</i> , 2012, 130, 1109-1119.	2.3	166
159	CD15 ⁺ /CD16 ^{low} human granulocytes from terminal cancer patients: granulocytic myeloid-derived suppressor cells that have suppressive function. <i>Tumor Biology</i> , 2012, 33, 121-129.	0.8	68
160	Immunological monitoring of the tumor immunoenvironment for clinical trials. <i>Cancer Immunology, Immunotherapy</i> , 2012, 61, 239-247.	2.0	24
161	Phenotype, function and clinical implications of myeloid-derived suppressor cells in cancer patients. <i>Cancer Immunology, Immunotherapy</i> , 2012, 61, 255-263.	2.0	230
162	Phase 2 study of neoadjuvant treatment with NOV-002 in combination with doxorubicin and cyclophosphamide followed by docetaxel in patients with HER-2 negative clinical stage IIa-IIIc breast cancer. <i>Breast Cancer Research and Treatment</i> , 2012, 132, 215-223.	1.1	94
163	Tumor microenvironment: a main actor in the metastasis process. <i>Clinical and Experimental Metastasis</i> , 2012, 29, 381-395.	1.7	155
164	Phase 1 studies of the safety and immunogenicity of electroporated HER2/CEA DNA vaccine followed by adenoviral boost immunization in patients with solid tumors. <i>Journal of Translational Medicine</i> , 2013, 11, 62.	1.8	70

#	ARTICLE	IF	CITATIONS
165	Abnormal T regulatory cells (Tregs: FOXP3+, CTLA-4+), myeloid-derived suppressor cells (MDSCs): Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 locally advanced breast cancers undergoing neoadjuvant chemotherapy (NAC) and surgery: failure of abolition of abnormal treg profile with treatment and correlation of treg levels with pathological response to NAC. <i>Journal of Translational Medicine</i> , 2013, 11, 16.	1.8	58
166	The Dark Side of Cyclophosphamide: Cyclophosphamide-Mediated Ablation of Regulatory T Cells. <i>Journal of Investigative Dermatology</i> , 2013, 133, 1462-1465.	0.3	19
167	Therapeutic Cancer Vaccines. <i>Advances in Cancer Research</i> , 2013, 119, 421-475.	1.9	450
168	The role and potential therapeutic application of myeloid-derived suppressor cells in TNBS-induced colitis. <i>Journal of Leukocyte Biology</i> , 2013, 94, 803-811.	1.5	50
169	Hypoxia-inducible factors as key regulators of tumor inflammation. <i>International Journal of Cancer</i> , 2013, 132, 2721-2729.	2.3	60
170	Increased Frequency of Myeloid-derived Suppressor Cells during Active Tuberculosis and after Recent Mycobacterium tuberculosis Infection Suppresses T-Cell Function. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2013, 188, 724-732.	2.5	149
171	Circulating Tumor Cells: From Bench to Bedside. <i>Annual Review of Medicine</i> , 2013, 64, 31-44.	5.0	85
172	Myeloid-derived suppressor cells: the dark knight or the joker in viral infections?. <i>Immunological Reviews</i> , 2013, 255, 210-221.	2.8	107
173	Increase in CD14+HLA-DR ^{hi} /low myeloid-derived suppressor cells in hepatocellular carcinoma patients and its impact on prognosis. <i>Cancer Immunology, Immunotherapy</i> , 2013, 62, 1421-1430.	2.0	231
174	Dendritic cell immunotherapy combined with gemcitabine chemotherapy enhances survival in a murine model of pancreatic carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2013, 62, 1083-1091.	2.0	64
175	Therapeutic regulation of myeloid-derived suppressor cells and immune response to cancer vaccine in patients with extensive stage small cell lung cancer. <i>Cancer Immunology, Immunotherapy</i> , 2013, 62, 909-918.	2.0	268
176	Vemurafenib reverses immunosuppression by myeloid derived suppressor cells. <i>International Journal of Cancer</i> , 2013, 133, 1653-1663.	2.3	107
177	Blockade of A2b Adenosine Receptor Reduces Tumor Growth and Immune Suppression Mediated by Myeloid-Derived Suppressor Cells in a Mouse Model of Melanoma. <i>Neoplasia</i> , 2013, 15, 1400-IN10.	2.3	132
178	Mac1+/Gr1+ cells contribute to transfusion-related acute lung injury. <i>Transfusion and Apheresis Science</i> , 2013, 49, 474-481.	0.5	0
179	Blood CD33(+)HLA-DR ^{hi} myeloid-derived suppressor cells are increased with age and a history of cancer. <i>Journal of Leukocyte Biology</i> , 2013, 93, 633-637.	1.5	199
180	Vaccination With ENO1 DNA Prolongs Survival of Genetically Engineered Mice With Pancreatic Cancer. <i>Gastroenterology</i> , 2013, 144, 1098-1106.	0.6	104
181	The Emerging Role of Immunosurveillance in Dictating Metastatic Spread in Breast Cancer. <i>Cancer Research</i> , 2013, 73, 5852-5857.	0.4	47
182	Microenvironmental regulation of tumor progression and metastasis. <i>Nature Medicine</i> , 2013, 19, 1423-1437.	15.2	5,730

#	ARTICLE	IF	CITATIONS
183	CXCR2-Expressing Myeloid-Derived Suppressor Cells Are Essential to Promote Colitis-Associated Tumorigenesis. <i>Cancer Cell</i> , 2013, 24, 631-644.	7.7	370
184	Myeloid derived suppressor cells in physiological and pathological conditions: the good, the bad, and the ugly. <i>Immunologic Research</i> , 2013, 57, 172-184.	1.3	89
185	Myeloid-Derived Suppressor Cells as a Vehicle for Tumor-Specific Oncolytic Viral Therapy. <i>Cancer Research</i> , 2013, 73, 5003-5015.	0.4	56
186	Cyclophosphamide Promotes Chronic Inflammation-Dependent Immunosuppression and Prevents Antitumor Response in Melanoma. <i>Journal of Investigative Dermatology</i> , 2013, 133, 1610-1619.	0.3	91
187	Myeloid-derived suppressor cells are associated with disease progression and decreased overall survival in advanced-stage melanoma patients. <i>Cancer Immunology, Immunotherapy</i> , 2013, 62, 1711-1722.	2.0	113
188	Cancer Immunotherapy. <i>Surgical Oncology Clinics of North America</i> , 2013, 22, 765-783.	0.6	27
189	History of myeloid-derived suppressor cells. <i>Nature Reviews Cancer</i> , 2013, 13, 739-752.	12.8	974
190	Fibrocytes represent a novel MDSC subset circulating in patients with metastatic cancer. <i>Blood</i> , 2013, 122, 1105-1113.	0.6	144
191	Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans. <i>Blood</i> , 2013, 121, 2975-2987.	0.6	335
192	The Effects of Exosomes and Related Vesicles on Cancer Development, Progression, and Dissemination. , 2013, , 107-129.		1
193	Chemoimmunotherapy: reengineering tumor immunity. <i>Cancer Immunology, Immunotherapy</i> , 2013, 62, 203-216.	2.0	215
194	Myeloid-Derived Suppressor Cells Play Crucial Roles in the Regulation of Mouse Collagen-Induced Arthritis. <i>Journal of Immunology</i> , 2013, 191, 1073-1081.	0.4	138
195	Regulation of accumulation and function of myeloid derived suppressor cells in different murine models of hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2013, 59, 1007-1013.	1.8	154
196	Circulating and intratumoral macrophages in patients with hepatocellular carcinoma: correlation with therapeutic approach. <i>American Journal of Surgery</i> , 2013, 205, 534-540.	0.9	5
197	Differential effects of smoking and COPD upon circulating myeloid derived suppressor cells. <i>Respiratory Medicine</i> , 2013, 107, 1895-1903.	1.3	22
198	The Emerging "Hallmarks" of Metabolic Reprogramming and Immune Evasion: Distinct or Linked?. <i>Cancer Research</i> , 2013, 73, 2737-2742.	0.4	98
199	The immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells. <i>Immunology</i> , 2013, 138, 105-115.	2.0	643
200	The kinship of neutrophils and granulocytic myeloid-derived suppressor cells in cancer: Cousins, siblings or twins?. <i>Seminars in Cancer Biology</i> , 2013, 23, 171-182.	4.3	143

#	ARTICLE	IF	CITATIONS
201	Myeloid derived suppressor cells. <i>Oncolimmunology</i> , 2013, 2, e24117.	2.1	63
202	Myeloid-derived suppressor cells have a central role in attenuated <i>Listeria monocytogenes</i> -based immunotherapy against metastatic breast cancer in young and old mice. <i>British Journal of Cancer</i> , 2013, 108, 2281-2290.	2.9	95
203	Increased CD14+HLA-DR-/low myeloid-derived suppressor cells correlate with extrathoracic metastasis and poor response to chemotherapy in non-small cell lung cancer patients. <i>Cancer Immunology, Immunotherapy</i> , 2013, 62, 1439-1451.	2.0	194
204	Myeloid-derived suppressor cells in cancer: recent progress and prospects. <i>Immunology and Cell Biology</i> , 2013, 91, 493-502.	1.0	196
205	<i>Cancer Immunotherapy</i> . , 2013, , 198-214.		2
206	Myeloid-derived suppressor cells in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2013, 140, 13-21.	1.1	143
207	<i>The Tumor Immunoenvironment</i> . , 2013, , .		4
208	Antitumor effects of anti-CD40/CpG immunotherapy combined with gemcitabine or 5-fluorouracil chemotherapy in the B16 melanoma model. <i>International Immunopharmacology</i> , 2013, 17, 1141-1147.	1.7	24
209	The Role of Anti-Inflammatory Drugs in Colorectal Cancer. <i>Annual Review of Medicine</i> , 2013, 64, 131-144.	5.0	108
210	Influence of human immune cells on cancer: studies at the University of Colorado. <i>Immunologic Research</i> , 2013, 55, 22-33.	1.3	13
211	Liposomal clodronate treatment for tumour macrophage depletion in dogs with soft-tissue sarcoma. <i>Veterinary and Comparative Oncology</i> , 2013, 11, 296-305.	0.8	24
212	Immunotherapy treatments for small-cell lung cancer: past, present and future. <i>Lung Cancer Management</i> , 2013, 2, 517-525.	1.5	1
213	Can pharmacological receptor tyrosine kinase inhibitors sensitize poor outcome breast tumors to immune-based therapies?. <i>Frontiers in Oncology</i> , 2013, 3, 23.	1.3	3
214	Immunosuppression involving increased myeloid-derived suppressor cell levels, systemic inflammation and hypoalbuminemia are present in patients with anaplastic thyroid cancer. <i>Molecular and Clinical Oncology</i> , 2013, 1, 959-964.	0.4	44
215	Hampering Immune Suppressors. <i>Cancer Journal (Sudbury, Mass)</i> , 2013, 19, 490-501.	1.0	56
216	A novel probe for the non-invasive detection of tumor-associated inflammation. <i>Oncolimmunology</i> , 2013, 2, e23034.	2.1	90
217	Tumor STAT1 Transcription Factor Activity Enhances Breast Tumor Growth and Immune Suppression Mediated by Myeloid-derived Suppressor Cells. <i>Journal of Biological Chemistry</i> , 2013, 288, 11676-11688.	1.6	107
218	<i>Emerging Concepts of Tumor Exosome-Mediated Cell-Cell Communication</i> . , 2013, , .		7

#	ARTICLE	IF	CITATIONS
219	Granulocytic myeloid-derived suppressor cells are cryosensitive and their frequency does not correlate with serum concentrations of colony-stimulating factors in head and neck cancer. <i>Innate Immunity</i> , 2013, 19, 328-336.	1.1	91
220	Pancreatic Cancer-Associated Stellate Cells Promote Differentiation of Myeloid-Derived Suppressor Cells in a STAT3-Dependent Manner. <i>Cancer Research</i> , 2013, 73, 3007-3018.	0.4	340
221	An Inflammatory Mediator, Prostaglandin E2, in Colorectal Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2013, 19, 502-510.	1.0	87
222	Tumor-Altered Dendritic Cell Function: Implications for Anti-Tumor Immunity. <i>Frontiers in Immunology</i> , 2013, 4, 192.	2.2	93
223	Clinical Perspectives on Targeting of Myeloid Derived Suppressor Cells in the Treatment of Cancer. <i>Frontiers in Oncology</i> , 2013, 3, 49.	1.3	133
224	Increased Myeloid-Derived Suppressor Cells in Gastric Cancer Correlate with Cancer Stage and Plasma S100A8/A9 Proinflammatory Proteins. <i>Journal of Immunology</i> , 2013, 190, 794-804.	0.4	216
225	Immunological monitoring of anticancer vaccines in clinical trials. <i>Oncolmmunology</i> , 2013, 2, e26012.	2.1	38
226	STAT3 activation. <i>Jak-stat</i> , 2013, 2, e23010.	2.2	159
227	A mutual activation loop between breast cancer cells and myeloid-derived suppressor cells facilitates spontaneous metastasis through IL-6 trans-signaling in a murine model. <i>Breast Cancer Research</i> , 2013, 15, R79.	2.2	126
228	Neutrophils and Myeloid-Derived Suppressor Cells in Cancer. , 2013, , 378-398.		0
229	Dendritic Cell-Based Immunotherapy for Glioma: Multiple Regimens and Implications in Clinical Trials. <i>Neurologia Medico-Chirurgica</i> , 2013, 53, 741-754.	1.0	19
230	Targeting immunosuppression for cancer therapy. <i>Journal of Clinical Investigation</i> , 2013, 123, 2355-2357.	3.9	53
231	A PK2/Bv8/PROK2 Antagonist Suppresses Tumorigenic Processes by Inhibiting Angiogenesis in Glioma and Blocking Myeloid Cell Infiltration in Pancreatic Cancer. <i>PLoS ONE</i> , 2013, 8, e54916.	1.1	43
232	Increased Level of Myeloid-Derived Suppressor Cells, Programmed Death Receptor Ligand 1/Programmed Death Receptor 1, and Soluble CD25 in Sokal High Risk Chronic Myeloid Leukemia. <i>PLoS ONE</i> , 2013, 8, e55818.	1.1	102
233	Peripheral Immune Cell Gene Expression Changes in Advanced Non-Small Cell Lung Cancer Patients Treated with First Line Combination Chemotherapy. <i>PLoS ONE</i> , 2013, 8, e57053.	1.1	20
234	Circulating and Tumor-Infiltrating Myeloid-Derived Suppressor Cells in Patients with Colorectal Carcinoma. <i>PLoS ONE</i> , 2013, 8, e57114.	1.1	232
235	Combining Antiangiogenic Therapy with Adoptive Cell Immunotherapy Exerts Better Antitumor Effects in Non-Small Cell Lung Cancer Models. <i>PLoS ONE</i> , 2013, 8, e65757.	1.1	49
236	The Impact of the Myeloid Response to Radiation Therapy. <i>Clinical and Developmental Immunology</i> , 2013, 2013, 1-14.	3.3	43

#	ARTICLE	IF	CITATIONS
237	Protumor Activities of the Immune Response: Insights in the Mechanisms of Immunological Shift, Oncotrainig, and Oncopromotion. <i>Journal of Oncology</i> , 2013, 2013, 1-16.	0.6	49
238	Immune suppression and evasion in patients with head and neck cancer. <i>Advances in Cellular and Molecular Otolaryngology</i> , 2013, 1, 21809.	0.4	3
239	Pancreatic Cancer Fostered Immunosuppression Privileges Tumor Growth and Progression. <i>Journal of Clinical & Cellular Immunology</i> , 2014, 05, .	1.5	3
240	IL-6-stimulated CD11b+CD14+HLA-DR ^{hi} myeloid-derived suppressor cells, are associated with progression and poor prognosis in squamous cell carcinoma of the esophagus. <i>Oncotarget</i> , 2014, 5, 8716-8728.	0.8	140
241	Complex role for the immune system in initiation and progression of pancreatic cancer. <i>World Journal of Gastroenterology</i> , 2014, 20, 11160.	1.4	111
242	Blockade of Fas Signaling in Breast Cancer Cells Suppresses Tumor Growth and Metastasis via Disruption of Fas Signaling-initiated Cancer-related Inflammation. <i>Journal of Biological Chemistry</i> , 2014, 289, 11522-11535.	1.6	24
243	Adjuvants and myeloid-derived suppressor cells: Enemies or allies in therapeutic cancer vaccination. <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 3251-3260.	1.4	37
244	Myeloid-derived cells are key targets of tumor immunotherapy. <i>Oncolmmunology</i> , 2014, 3, e28398.	2.1	47
245	Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer. <i>Cell Death and Differentiation</i> , 2014, 21, 15-25.	5.0	740
246	Monocytic myeloid-derived suppressor cells in advanced melanoma patients. <i>Oncolmmunology</i> , 2014, 3, e27845.	2.1	17
247	DC-HIL + CD14 + HLA-DR no/low Cells Are a Potential Blood Marker and Therapeutic Target for Melanoma. <i>Journal of Investigative Dermatology</i> , 2014, 134, 2839-2842.	0.3	11
248	Adaptive immune contexture at the tumour site and downmodulation of circulating myeloid-derived suppressor cells in the response of solitary fibrous tumour patients to anti-angiogenic therapy. <i>British Journal of Cancer</i> , 2014, 111, 1350-1362.	2.9	21
249	Myeloid-Derived Suppressor Cells Predict Survival of Patients with Advanced Melanoma: Comparison with Regulatory T Cells and NY-ESO-1- or Melan-A ^{hi} -Specific T Cells. <i>Clinical Cancer Research</i> , 2014, 20, 1601-1609.	3.2	222
250	Exploiting Synergy: Immune-Based Combinations in the Treatment of Prostate Cancer. <i>Frontiers in Oncology</i> , 2014, 4, 351.	1.3	15
251	Orchestration of Angiogenesis by Immune Cells. <i>Frontiers in Oncology</i> , 2014, 4, 131.	1.3	99
252	Oncolytic Viruses as Anticancer Vaccines. <i>Frontiers in Oncology</i> , 2014, 4, 188.	1.3	65
253	DC-HIL-Expressing Myelomonocytic Cells Are Critical Promoters of Melanoma Growth. <i>Journal of Investigative Dermatology</i> , 2014, 134, 2784-2794.	0.3	23
254	Combinations of Immunotherapy and Radiation in Cancer Therapy. <i>Frontiers in Oncology</i> , 2014, 4, 325.	1.3	205

#	ARTICLE	IF	CITATIONS
255	Specific Inhibition of the VEGFR-3 Tyrosine Kinase by SAR131675 Reduces Peripheral and Tumor Associated Immunosuppressive Myeloid Cells. <i>Cancers</i> , 2014, 6, 472-490.	1.7	28
256	Dissecting the Role of Bone Marrow Stromal Cells on Bone Metastases. <i>BioMed Research International</i> , 2014, 2014, 1-11.	0.9	26
257	Targeting CD8 ⁺ T-cell tolerance for cancer immunotherapy. <i>Immunotherapy</i> , 2014, 6, 833-852.	1.0	41
258	New Approaches in Immunotherapy for the Treatment of Lung Cancer. <i>Current Topics in Microbiology and Immunology</i> , 2014, 405, 1-31.	0.7	9
259	Computational Algorithm-Driven Evaluation of Monocytic Myeloid-Derived Suppressor Cell Frequency for Prediction of Clinical Outcomes. <i>Cancer Immunology Research</i> , 2014, 2, 812-821.	1.6	122
260	Review of psychotherapeutic interventions on depression in cancer patients and their impact on disease progression. <i>International Review of Psychiatry</i> , 2014, 26, 31-43.	1.4	59
261	Adoptive cellular therapy of cancer: exploring innate and adaptive cellular crosstalk to improve anti-tumor efficacy. <i>Future Oncology</i> , 2014, 10, 1779-1794.	1.1	12
262	Tumour-induced immune suppression: role of inflammatory mediators released by myelomonocytic cells. <i>Journal of Internal Medicine</i> , 2014, 276, 154-170.	2.7	53
263	Immune regulation of bone metastasis. <i>BoneKey Reports</i> , 2014, 3, 600.	2.7	28
264	Ageing and myeloid-derived suppressor cells: possible involvement in immunosenescence and age-related disease. <i>Age</i> , 2014, 36, 9729.	3.0	72
265	Increased circulating low CD ³³ ⁺ HLA-DR ⁺ myeloid-derived suppressor cells in hepatocellular carcinoma patients. <i>Hepatology Research</i> , 2014, 44, 639-650.	1.8	60
266	Correlation between frequencies of blood monocytic myeloid-derived suppressor cells, regulatory T cells and negative prognostic markers in patients with castration-resistant metastatic prostate cancer. <i>Cancer Immunology, Immunotherapy</i> , 2014, 63, 1177-1187.	2.0	135
267	Complexity and challenges in defining myeloid-derived suppressor cells. , 2014, , n/a-n/a.		102
268	Enhanced suppressive capacity of tumor-infiltrating myeloid-derived suppressor cells compared with their peripheral counterparts. <i>International Journal of Cancer</i> , 2014, 134, 1077-1090.	2.3	62
269	A Feasibility Study of Cyclophosphamide, Trastuzumab, and an Allogeneic GM-CSF ⁺ Secreting Breast Tumor Vaccine for HER2+ Metastatic Breast Cancer. <i>Cancer Immunology Research</i> , 2014, 2, 949-961.	1.6	77
270	Myeloid-Derived Suppressor Cells in the Development of Lung Cancer. <i>Cancer Immunology Research</i> , 2014, 2, 50-58.	1.6	95
271	Myeloid derived suppressor and dendritic cell subsets are related to clinical outcome in prostate cancer patients treated with prostate GVAX and ipilimumab. , 2014, 2, 31.		92
272	Myeloid-derived suppressor cells link inflammation to cancer. <i>Oncolmmunology</i> , 2014, 3, e28581.	2.1	7

#	ARTICLE	IF	CITATIONS
273	Cyclophosphamide and IL-12-transduced DCs Enhance the Antitumor Activity of Tumor Antigen- α -stimulated DCs and Reduce Tregs and MDSCs Number. <i>Journal of Immunotherapy</i> , 2014, 37, 427-439.	1.2	23
274	Chemotherapy-induced myeloid suppressor cells and antitumor immunity: The Janus face of chemotherapy in immunomodulation. <i>OncolImmunology</i> , 2014, 3, e954471.	2.1	32
275	DNA demethylating agent 5-azacytidine inhibits myeloid-derived suppressor cells induced by tumor growth and cyclophosphamide treatment. <i>Journal of Leukocyte Biology</i> , 2014, 95, 743-753.	1.5	43
276	Location, location, location: functional and phenotypic heterogeneity between tumor-infiltrating and non-infiltrating myeloid-derived suppressor cells. <i>OncolImmunology</i> , 2014, 3, e956579.	2.1	60
277	Myeloid-Derived Suppressor Cells as Therapeutic Target in Hematological Malignancies. <i>Frontiers in Oncology</i> , 2014, 4, 349.	1.3	92
278	The Impact of the Immune System on Tumor: Angiogenesis and Vascular Remodeling. <i>Frontiers in Oncology</i> , 2014, 4, 69.	1.3	129
279	Neutrophils with myeloid derived suppressor function deplete arginine and constrain T cell function in septic shock patients. <i>Critical Care</i> , 2014, 18, R163.	2.5	166
280	Tumor-conditioned Gr-1+CD11b+ myeloid cells induce angiogenesis through the synergistic action of CCL2 and CXCL16 in vitro. <i>Biochemical and Biophysical Research Communications</i> , 2014, 443, 1218-1225.	1.0	16
281	The synthetic retinoid Am80 delays recovery in a model of multiple sclerosis by modulating myeloid-derived suppressor cell fate and viability. <i>Neurobiology of Disease</i> , 2014, 67, 149-164.	2.1	29
282	HIF- β /MIF and NF- κ B/IL-6 Axes Contribute to the Recruitment of CD11b+Gr-1+ Myeloid Cells in Hypoxic Microenvironment of HNSCC. <i>Neoplasia</i> , 2014, 16, 168-W21.	2.3	54
283	Monocyte-Derived Cells of the Brain and Malignant Gliomas: The Double Face of Janus. <i>World Neurosurgery</i> , 2014, 82, 1171-1186.	0.7	24
284	Minding the body: Psychotherapy and cancer survival. <i>British Journal of Health Psychology</i> , 2014, 19, 465-485.	1.9	34
285	Harnessing the immune system for the treatment of breast cancer. <i>Journal of Zhejiang University: Science B</i> , 2014, 15, 1-15.	1.3	29
286	Chronic inflammation and cancer: suppressing the suppressors. <i>Cancer Immunology, Immunotherapy</i> , 2014, 63, 11-20.	2.0	87
287	The significant increase and dynamic changes of the myeloid-derived suppressor cells percentage with chemotherapy in advanced NSCLC patients. <i>Clinical and Translational Oncology</i> , 2014, 16, 616-622.	1.2	12
288	Identification of CD244-expressing myeloid-derived suppressor cells in patients with active tuberculosis. <i>Immunology Letters</i> , 2014, 158, 66-72.	1.1	35
289	Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab. <i>Cancer Immunology, Immunotherapy</i> , 2014, 63, 247-257.	2.0	472
290	The effects of gemcitabine and capecitabine combination chemotherapy and of low-dose adjuvant GM-CSF on the levels of myeloid-derived suppressor cells in patients with advanced pancreatic cancer. <i>Cancer Immunology, Immunotherapy</i> , 2014, 63, 175-183.	2.0	80

#	ARTICLE	IF	CITATIONS
291	Signaling pathways involved in MDSC regulation. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2014, 1846, 55-65.	3.3	152
293	Breaking immunotolerance of tumors: A new perspective for dendritic cell therapy. <i>Journal of Immunotoxicology</i> , 2014, 11, 311-318.	0.9	36
294	Interaction of Immune and Cancer Cells. , 2014, , .		0
295	Clinical evaluation of systemic and local immune responses in cancer: time for integration. <i>Cancer Immunology, Immunotherapy</i> , 2014, 63, 45-57.	2.0	56
296	Tumor Microenvironment and Cellular Stress. <i>Advances in Experimental Medicine and Biology</i> , 2014, 772, v-viii.	0.8	29
297	Primary 4T1 tumor resection provides critical "window of opportunity" for immunotherapy. <i>Clinical and Experimental Metastasis</i> , 2014, 31, 185-198.	1.7	22
298	Graft Monocytic Myeloid-Derived Suppressor Cell Content Predicts the Risk of Acute Graft-versus-Host Disease after Allogeneic Transplantation of Granulocyte Colony-Stimulating Factor-Mobilized Peripheral Blood Stem Cells. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 2049-2055.	2.0	60
299	Infiltrating S100A8+ myeloid cells promote metastatic spread of human breast cancer and predict poor clinical outcome. <i>Breast Cancer Research and Treatment</i> , 2014, 148, 41-59.	1.1	40
300	CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets. <i>Blood</i> , 2014, 123, 3016-3026.	0.6	220
301	Phenotypes, accumulation, and functions of myeloid-derived suppressor cells and associated treatment strategies in cancer patients. <i>Human Immunology</i> , 2014, 75, 1128-1137.	1.2	55
302	Hypoxia-inducible factors in regulation of immune responses in tumour microenvironment. <i>Immunology</i> , 2014, 143, 512-519.	2.0	270
303	BMP4 Inhibits Breast Cancer Metastasis by Blocking Myeloid-Derived Suppressor Cell Activity. <i>Cancer Research</i> , 2014, 74, 5091-5102.	0.4	99
304	Stromal-dependent tumor promotion by MIF family members. <i>Cellular Signalling</i> , 2014, 26, 2969-2978.	1.7	18
305	Paclitaxel Therapy Promotes Breast Cancer Metastasis in a TLR4-Dependent Manner. <i>Cancer Research</i> , 2014, 74, 5421-5434.	0.4	196
306	Functional significance of mononuclear phagocyte populations generated through adult hematopoiesis. <i>Journal of Leukocyte Biology</i> , 2014, 96, 969-980.	1.5	22
307	Impact of myeloid cells on the efficacy of anticancer chemotherapy. <i>Current Opinion in Immunology</i> , 2014, 30, 24-31.	2.4	35
308	Myeloid-derived suppressor cell heterogeneity in human cancers. <i>Annals of the New York Academy of Sciences</i> , 2014, 1319, 47-65.	1.8	349
309	TGF β 2 in T cell biology and tumor immunity: Angel or devil?. <i>Cytokine and Growth Factor Reviews</i> , 2014, 25, 423-435.	3.2	81

#	ARTICLE	IF	CITATIONS
310	Direct incorporation of the NKT-cell activator α -galactosylceramide into a recombinant <i>Listeria monocytogenes</i> improves breast cancer vaccine efficacy. <i>British Journal of Cancer</i> , 2014, 111, 1945-1954.	2.9	29
311	Stromal reengineering to treat pancreas cancer. <i>Carcinogenesis</i> , 2014, 35, 1451-1460.	1.3	108
312	Molecular Pathways: Myeloid Complicity in Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 5157-5170.	3.2	44
313	Mammary Gland Involution as an Immunotherapeutic Target for Postpartum Breast Cancer. <i>Journal of Mammary Gland Biology and Neoplasia</i> , 2014, 19, 213-228.	1.0	40
314	Uterine Cervical Cancer Displaying Tumor-Related Leukocytosis: A Distinct Clinical Entity With Radioresistant Feature. <i>Journal of the National Cancer Institute</i> , 2014, 106, dju147-dju147.	3.0	102
315	Galectin-3 contributes to cisplatin-induced myeloid derived suppressor cells (MDSCs) recruitment in Lewis lung cancer-bearing mice. <i>Molecular Biology Reports</i> , 2014, 41, 4069-4076.	1.0	22
316	Targeted depletion of an MDSC subset unmasks pancreatic ductal adenocarcinoma to adaptive immunity. <i>Gut</i> , 2014, 63, 1769-1781.	6.1	272
317	Myeloid-Derived Suppressor Cells in Cancer: Therapeutic, Predictive, and Prognostic Implications. <i>Seminars in Oncology</i> , 2014, 41, 174-184.	0.8	147
318	Immunosuppressive Myeloid Cells Induced by Chemotherapy Attenuate Antitumor CD4+ T-Cell Responses through the PD-1/PD-L1 Axis. <i>Cancer Research</i> , 2014, 74, 3441-3453.	0.4	115
319	Mast cell histamine promotes the immunoregulatory activity of myeloid-derived suppressor cells. <i>Journal of Leukocyte Biology</i> , 2014, 96, 151-159.	1.5	48
320	Haematopoietic focal adhesion kinase deficiency alters haematopoietic homeostasis to drive tumour metastasis. <i>Nature Communications</i> , 2014, 5, 5054.	5.8	17
321	Cancer-related inflammation and treatment effectiveness. <i>Lancet Oncology</i> , The, 2014, 15, e493-e503.	5.1	1,525
322	Tumor-Induced Immune Suppression. , 2014, , .		3
323	Analysis of HLA-G gene polymorphism and protein expression in invasive breast ductal carcinoma. <i>Human Immunology</i> , 2014, 75, 667-672.	1.2	37
324	Inhibition of Tumor-Derived Prostaglandin-E2 Blocks the Induction of Myeloid-Derived Suppressor Cells and Recovers Natural Killer Cell Activity. <i>Clinical Cancer Research</i> , 2014, 20, 4096-4106.	3.2	230
325	Granulocytic myeloid derived suppressor cells expand in human pregnancy and modulate T cell responses. <i>European Journal of Immunology</i> , 2014, 44, 2582-2591.	1.6	143
326	The proportion and function of peripheral myeloid-derived suppressor cells do not correlate with systemic inflammation in chronic obstructive pulmonary disease. <i>Human Immunology</i> , 2014, 75, 5-9.	1.2	4
327	Recent Advancement in Understanding Colitis-associated Tumorigenesis. <i>Inflammatory Bowel Diseases</i> , 2014, 20, 2115-2123.	0.9	25

#	ARTICLE	IF	CITATIONS
328	Functional characterization of myeloid-derived suppressor cell subpopulations during the development of experimental arthritis. <i>European Journal of Immunology</i> , 2015, 45, 464-473.	1.6	37
329	MicroRNA-155 deficiency enhances the recruitment and functions of myeloid-derived suppressor cells in tumor microenvironment and promotes solid tumor growth. <i>International Journal of Cancer</i> , 2015, 136, E602-13.	2.3	91
331	The significance of G-CSF expression and myeloid-derived suppressor cells in the chemoresistance of uterine cervical cancer. <i>Scientific Reports</i> , 2015, 5, 18217.	1.6	126
332	Prognostic and Predictive Significance of Stromal Fibroblasts and Macrophages in Colon Cancer. <i>Biomarkers in Cancer</i> , 2015, 7, 1, BIC.S25247.	3.6	9
333	IL-11 induces differentiation of myeloid-derived suppressor cells through activation of STAT3 signalling pathway. <i>Scientific Reports</i> , 2015, 5, 13650.	1.6	18
334	Increase in Both CD14-Positive and CD15-Positive Myeloid-Derived Suppressor Cell Subpopulations in the Blood of Patients With Glioma But Predominance of CD15-Positive Myeloid-Derived Suppressor Cells in Glioma Tissue. <i>Journal of Neuropathology and Experimental Neurology</i> , 2015, 74, 390-400.	0.9	98
335	Soluble factors regulated by epithelial-mesenchymal transition mediate tumour angiogenesis and myeloid cell recruitment. <i>Journal of Pathology</i> , 2015, 236, 491-504.	2.1	51
336	Polysaccharide <i>Agaricus blazei</i> Murill stimulates myeloid derived suppressor cell differentiation from M2 to M1 type, which mediates inhibition of tumour immune evasion via the Toll-like receptor 2 pathway. <i>Immunology</i> , 2015, 146, 379-391.	2.0	43
337	Peripheral myeloid-derived suppressor and T regulatory PD-1 positive cells predict response to neoadjuvant short-course radiotherapy in rectal cancer patients. <i>Oncotarget</i> , 2015, 6, 8261-8270.	0.8	54
338	Exploiting the Immunomodulatory Properties of Chemotherapeutic Drugs to Improve the Success of Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 2015, 6, 516.	2.2	79
339	Enhanced NK cell adoptive antitumor effects against breast cancer in vitro via blockade of the transforming growth factor- β signaling pathway. <i>OncoTargets and Therapy</i> , 2015, 8, 1553.	1.0	26
340	Plasticity of neutrophils reveals modulatory capacity. <i>Brazilian Journal of Medical and Biological Research</i> , 2015, 48, 665-675.	0.7	41
341	Systemic Monocytic-MDSCs Are Generated from Monocytes and Correlate with Disease Progression in Breast Cancer Patients. <i>PLoS ONE</i> , 2015, 10, e0127028.	1.1	116
342	Rapamycin Promotes Mouse 4T1 Tumor Metastasis that Can Be Reversed by a Dendritic Cell-Based Vaccine. <i>PLoS ONE</i> , 2015, 10, e0138335.	1.1	15
343	Myeloid-Derived Suppressor Cells and Therapeutic Strategies in Cancer. <i>Mediators of Inflammation</i> , 2015, 2015, 1-12.	1.4	80
344	Pre- and post-operative evaluation: percentages of circulating myeloid-derived suppressor cells in rectal cancer patients. <i>Neoplasma</i> , 2015, 62, 239-249.	0.7	13
345	Adjuvant Immunotherapy With Autologous Cytokine-Induced Killer Cells for Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2015, 148, 1383-1391.e6.	0.6	371
346	The Role of TLR4 in Chemotherapy-Driven Metastasis. <i>Cancer Research</i> , 2015, 75, 2405-2410.	0.4	97

#	ARTICLE	IF	CITATIONS
347	Phenylhydrazine administration accelerates the development of experimental cerebral malaria. <i>Experimental Parasitology</i> , 2015, 156, 1-11.	0.5	7
348	TLR9-Targeted STAT3 Silencing Abrogates Immunosuppressive Activity of Myeloid-Derived Suppressor Cells from Prostate Cancer Patients. <i>Clinical Cancer Research</i> , 2015, 21, 3771-3782.	3.2	152
349	Myeloid-Derived Suppressor Cells. <i>Advances in Cancer Research</i> , 2015, 128, 95-139.	1.9	419
350	Inflammatory and Innate Immune Cells in Cancer Microenvironment and Progression. , 2015, , 9-28.		6
351	<i>CCR</i> 20th Anniversary Commentary: Setting the Stage for Nanoparticle Albumin-Bound Paclitaxelâ€”How Far Science Has Come. <i>Clinical Cancer Research</i> , 2015, 21, 1975-1977.	3.2	2
352	A phase I/IIa study of adjuvant immunotherapy with tumour antigen-pulsed dendritic cells in patients with hepatocellular carcinoma. <i>British Journal of Cancer</i> , 2015, 113, 1666-1676.	2.9	73
353	The combination of dendritic cells-cytotoxic T lymphocytes/cytokine-induced killer (DC-CTL/CIK) therapy exerts immune and clinical responses in patients with malignant tumors. <i>Experimental Hematology and Oncology</i> , 2015, 4, 32.	2.0	27
354	The role of inflammation in progression of breast cancer: Friend or foe? (Review). <i>International Journal of Oncology</i> , 2015, 47, 797-805.	1.4	52
355	Correlation between myeloid-derived suppressor cells and S100A8/A9 in tumor and autoimmune diseases. <i>International Immunopharmacology</i> , 2015, 29, 919-925.	1.7	13
356	Myeloid-derived suppressor cells: their role in the pathophysiology of hematologic malignancies and potential as therapeutic targets. <i>Leukemia and Lymphoma</i> , 2015, 56, 2251-2263.	0.6	29
357	Complexity and challenges in defining myeloid-derived suppressor cells. , 2015, 88, 77-91.		119
358	Tumor-induced CD14+HLA-DRâ€”/low myeloid-derived suppressor cells correlate with tumor progression and outcome of therapy in multiple myeloma patients. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 389-399.	2.0	79
359	Carbonic Anhydrase IX Promotes Myeloid-Derived Suppressor Cell Mobilization and Establishment of a Metastatic Niche by Stimulating G-CSF Production. <i>Cancer Research</i> , 2015, 75, 996-1008.	0.4	111
360	Lenalidomide and cyclophosphamide immunoregulation in patients with metastatic, castration-resistant prostate cancer. <i>Clinical and Experimental Metastasis</i> , 2015, 32, 111-124.	1.7	17
361	General anesthesia combined with epidural anesthesia ameliorates the effect of fast-track surgery by mitigating immunosuppression and facilitating intestinal functional recovery in colon cancer patients. <i>International Journal of Colorectal Disease</i> , 2015, 30, 475-481.	1.0	61
362	Invasive breast cancer reprograms early myeloid differentiation in the bone marrow to generate immunosuppressive neutrophils. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, E566-75.	3.3	329
363	Inflammation and Cancer. , 2015, , 285-296.e3.		0
364	The role of STAT3 in tumor-mediated immune suppression. <i>Journal of Neuro-Oncology</i> , 2015, 123, 385-394.	1.4	55

#	ARTICLE	IF	CITATIONS
365	Drug-induced allergic hepatitis develops in mice when myeloid-derived suppressor cells are depleted prior to halothane treatment. <i>Hepatology</i> , 2015, 62, 546-557.	3.6	54
366	The Tyrosine Kinase Inhibitors Imatinib and Dasatinib Reduce Myeloid Suppressor Cells and Release Effector Lymphocyte Responses. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 1181-1191.	1.9	71
367	Natural killer T cell activation overcomes immunosuppression to enhance clearance of postsurgical breast cancer metastasis in mice. <i>Oncolmmunology</i> , 2015, 4, e995562.	2.1	46
368	Poly (I: C) modulates the immunosuppressive activity of myeloid-derived suppressor cells in a murine model of breast cancer. <i>Breast Cancer Research and Treatment</i> , 2015, 153, 21-30.	1.1	38
369	Big opportunities for small molecules in immuno-oncology. <i>Nature Reviews Drug Discovery</i> , 2015, 14, 603-622.	21.5	369
370	CCL2 Promotes Colorectal Carcinogenesis by Enhancing Polymorphonuclear Myeloid-Derived Suppressor Cell Population and Function. <i>Cell Reports</i> , 2015, 12, 244-257.	2.9	287
371	Complement C3 mediated targeting of liposomes to granulocytic myeloid derived suppressor cells. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2015, 11, 1355-1363.	1.7	27
372	Activation of neuroimmune pathways increases therapeutic effects of radiotherapy on poorly differentiated breast carcinoma. <i>Brain, Behavior, and Immunity</i> , 2015, 48, 174-185.	2.0	22
373	Granulocytic subset of myeloid derived suppressor cells in rats with mammary carcinoma. <i>Cellular Immunology</i> , 2015, 295, 29-35.	1.4	17
374	Liver myeloid-derived suppressor cells expand in response to liver metastases in mice and inhibit the anti-tumor efficacy of anti-CEA CAR-T. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 817-829.	2.0	184
375	Highlights on mechanisms of drugs targeting MDSCs: providing a novel perspective on cancer treatment. <i>Tumor Biology</i> , 2015, 36, 3159-3169.	0.8	9
376	Presence of circulating Her2-reactive CD8 ⁺ T-cells is associated with lower frequencies of myeloid-derived suppressor cells and regulatory T cells, and better survival in older breast cancer patients. <i>Breast Cancer Research</i> , 2015, 17, 34.	2.2	63
377	Circulating CD14 ⁺ HLA-DR ^{low} myeloid-derived suppressor cell is an indicator of poor prognosis in patients with ESCC. <i>Tumor Biology</i> , 2015, 36, 7987-7996.	0.8	30
378	Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in <i>BRAF</i> ^{V600E} melanoma. <i>Science Translational Medicine</i> , 2015, 7, 279ra41.	5.8	470
379	TLR5 Ligand-Secreting T Cells Reshape the Tumor Microenvironment and Enhance Antitumor Activity. <i>Cancer Research</i> , 2015, 75, 1959-1971.	0.4	33
380	The Great Escape; the Hallmarks of Resistance to Antiangiogenic Therapy. <i>Pharmacological Reviews</i> , 2015, 67, 441-461.	7.1	190
381	Myeloid derived suppressor cells—An overview of combat strategies to increase immunotherapy efficacy. <i>Oncolmmunology</i> , 2015, 4, e954829.	2.1	219
382	Myeloid-Derived Suppressor Cells as an Immune Parameter in Patients with Concurrent Sunitinib and Stereotactic Body Radiotherapy. <i>Clinical Cancer Research</i> , 2015, 21, 4073-4085.	3.2	97

#	ARTICLE	IF	CITATIONS
383	Vaccine-Induced Tumor Necrosis Factor-Producing T Cells Synergize with Cisplatin to Promote Tumor Cell Death. <i>Clinical Cancer Research</i> , 2015, 21, 781-794.	3.2	81
384	Immunologic Correlates in the Course of Treatment With Immunomodulating Antibodies. <i>Seminars in Oncology</i> , 2015, 42, 448-458.	0.8	22
385	Immune-mediated mechanisms influencing the efficacy of anticancer therapies. <i>Trends in Immunology</i> , 2015, 36, 198-216.	2.9	121
386	The nitric oxide radical scavenger carboxy-PTIO reduces the immunosuppressive activity of myeloid-derived suppressor cells and potentiates the antitumor activity of adoptive cytotoxic T lymphocyte immunotherapy. <i>OncImmunology</i> , 2015, 4, e1019195.	2.1	20
387	Immunosuppression associated with chronic inflammation in the tumor microenvironment. <i>Carcinogenesis</i> , 2015, 36, 1085-1093.	1.3	261
388	A subpopulation that may correspond to granulocytic myeloid-derived suppressor cells reflects the clinical stage and progression of cutaneous melanoma. <i>International Immunology</i> , 2016, 28, 87-97.	1.8	21
389	Immunological factors influencing clinical outcome in lung cancer patients after telomerase peptide vaccination. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 1609-1621.	2.0	42
390	CpG expedites regression of local and systemic tumors when combined with activatable nanodelivery. <i>Journal of Controlled Release</i> , 2015, 220, 253-264.	4.8	26
391	Expansion of Myeloid-Derived Suppressor Cells in Patients with Acute Coronary Syndrome. <i>Cellular Physiology and Biochemistry</i> , 2015, 35, 292-304.	1.1	22
392	Id1 suppresses anti-tumour immune responses and promotes tumour progression by impairing myeloid cell maturation. <i>Nature Communications</i> , 2015, 6, 6840.	5.8	87
393	Perivascular M2 Macrophages Stimulate Tumor Relapse after Chemotherapy. <i>Cancer Research</i> , 2015, 75, 3479-3491.	0.4	375
394	Myeloid-derived suppressor cells in human peripheral blood: Optimized quantification in healthy donors and patients with metastatic renal cell carcinoma. <i>Immunology Letters</i> , 2015, 168, 260-267.	1.1	20
395	Increase in myeloid-derived suppressor cells (MDSCs) associated with minimal residual disease (MRD) detection in adult acute myeloid leukemia. <i>International Journal of Hematology</i> , 2015, 102, 579-586.	0.7	69
396	Targeting the bone marrow microenvironment in multiple myeloma. <i>Immunological Reviews</i> , 2015, 263, 160-172.	2.8	323
397	Balancing the innate immune system in tumor development. <i>Trends in Cell Biology</i> , 2015, 25, 214-220.	3.6	107
398	Tumor-induced myeloid dysfunction and its implications for cancer immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 1-13.	2.0	104
399	Activation of mTOR pathway in myeloid-derived suppressor cells stimulates cancer cell proliferation and metastasis in <i>lala^{+/+}/ã^{-/-}</i> mice. <i>Oncogene</i> , 2015, 34, 1938-1948.	2.6	58
400	Ameliorative effect of propolis against cyclophosphamide-induced toxicity in mice. <i>Pharmaceutical Biology</i> , 2015, 53, 235-241.	1.3	39

#	ARTICLE	IF	CITATIONS
401	Dopamine inhibits the function of Gr-1+CD115+ myeloid-derived suppressor cells through D1-like receptors and enhances anti-tumor immunity. <i>Journal of Leukocyte Biology</i> , 2015, 97, 191-200.	1.5	29
402	Regulation of Tumor Metastasis by Myeloid-Derived Suppressor Cells. <i>Annual Review of Medicine</i> , 2015, 66, 97-110.	5.0	406
403	Myeloid regulatory cells in tumor spreading and metastasis. <i>Immunobiology</i> , 2015, 220, 236-242.	0.8	105
404	Immunotherapy in Colorectal Cancer. , 2016, , .		0
405	Indoleamine 2,3-dioxygenase (IDO): Biology and Target in Cancer Immunotherapies. <i>Current Cancer Drug Targets</i> , 2016, 16, 755-764.	0.8	64
406	Tumour progression and metastasis. <i>Ecancermedicalscience</i> , 2016, 10, 617.	0.6	57
407	Cancer immunotherapy via combining oncolytic virotherapy with chemotherapy: recent advances. <i>Oncolytic Virotherapy</i> , 2016, 5, 1.	6.0	56
408	Extracellular vesicle cross-talk in the bone marrow microenvironment: implications in multiple myeloma. <i>Oncotarget</i> , 2016, 7, 38927-38945.	0.8	53
409	Myeloid cell signatures in tumor microenvironment predicts therapeutic response in cancer. <i>OncoTargets and Therapy</i> , 2016, 9, 1047.	1.0	30
410	Myeloid-derived suppressor cells are elevated in patients with psoriasis and produce various molecules. <i>Molecular Medicine Reports</i> , 2016, 14, 3935-3940.	1.1	20
411	Suppressive role of myeloid-derived suppressor cells (MDSCs) in the microenvironment of breast cancer and targeted immunotherapies. <i>Oncotarget</i> , 2016, 7, 64505-64511.	0.8	81
412	Ferulic Acid against Cyclophosphamide-Induced Heart Toxicity in Mice by Inhibiting NF- κ B Pathway. <i>Evidence-based Complementary and Alternative Medicine</i> , 2016, 2016, 1-8.	0.5	32
413	Overcoming Hypoxia-Mediated Tumor Progression: Combinatorial Approaches Targeting pH Regulation, Angiogenesis and Immune Dysfunction. <i>Frontiers in Cell and Developmental Biology</i> , 2016, 4, 27.	1.8	107
414	Increased Levels of Circulating and Tumor-Infiltrating Granulocytic Myeloid Cells in Colorectal Cancer Patients. <i>Frontiers in Immunology</i> , 2016, 7, 560.	2.2	58
415	The IL-8/IL-8R Axis: A Double Agent in Tumor Immune Resistance. <i>Vaccines</i> , 2016, 4, 22.	2.1	286
416	Immunostimulatory Effects of Melphalan and Usefulness in Adoptive Cell Therapy with Antitumor CD4+ T Cells. <i>Critical Reviews in Immunology</i> , 2016, 36, 179-191.	1.0	23
417	Relevance of Interferon Regulatory Factor-8 Expression in Myeloid-Tumor Interactions. <i>Journal of Interferon and Cytokine Research</i> , 2016, 36, 442-453.	0.5	19
418	Myeloid-derived suppressor cells as effectors of immune suppression in cancer. <i>International Journal of Cancer</i> , 2016, 139, 1915-1926.	2.3	80

#	ARTICLE	IF	CITATIONS
419	<sc>CD</sc>33⁺/<sc>HLA</sc>â€<sc>DR</sc>^{neg} and <sc>CD</sc>33⁺/<sc>HLA</sc>â€<sc>DR</sc>⁺ Cells: Rare Populations in the Human Decidua with Characteristics of <sc>MDSC</sc>. American Journal of Reproductive Immunology, 2016, 75, 539-556.	1.2	24
420	Immunotherapy for breast cancer: past, present, and future. Cancer and Metastasis Reviews, 2016, 35, 525-546.	2.7	49
421	Tumor-Induced Myeloid-Derived Suppressor Cells. Microbiology Spectrum, 2016, 4, .	1.2	28
422	Role of immune cells in pancreatic cancer from bench to clinical application. Medicine (United States), 2016, 95, e5541.	0.4	118
423	GMâ€CSF signalling blockade and chemotherapeutic agents act in concert to inhibit the function of myeloidâ€derived suppressor cells <i>in vitro</i>. Clinical and Translational Immunology, 2016, 5, e119.	1.7	30
424	Targeting regulatory T cells in tumors. FEBS Journal, 2016, 283, 2731-2748.	2.2	179
425	Circulating myeloid-derived suppressor cells in patients with pancreatic cancer. Hepatobiliary and Pancreatic Diseases International, 2016, 15, 099-105.	0.6	41
426	Effect of First-Line Treatment on Myeloid-Derived Suppressor Cellsâ€™ Subpopulations in the Peripheral Blood of Patients with Nonâ€Small Cell Lung Cancer. Journal of Thoracic Oncology, 2016, 11, 1263-1272.	0.5	81
427	Oncogenic mTOR signalling recruits myeloid-derived suppressor cells to promote tumour initiation. Nature Cell Biology, 2016, 18, 632-644.	4.6	174
428	Cutaneous squamous cell carcinomas with markers of increased metastatic risk are associated with elevated numbers of neutrophils and/or granulocytic myeloid derived suppressor cells. Journal of Dermatological Science, 2016, 83, 124-130.	1.0	16
429	Human MDSCs. SpringerBriefs in Immunology, 2016, , 39-48.	0.1	1
430	The Contribution of Cholesterol and Its Metabolites to the Pathophysiology of Breast Cancer. Hormones and Cancer, 2016, 7, 219-228.	4.9	42
431	Myeloid-Derived Suppressor Cells Endow Stem-like Qualities to Breast Cancer Cells through IL6/STAT3 and NO/NOTCH Cross-talk Signaling. Cancer Research, 2016, 76, 3156-3165.	0.4	224
432	Human neutrophils: Their role in cancer and relation to myeloid-derived suppressor cells. Seminars in Immunology, 2016, 28, 187-196.	2.7	257
433	Myeloid-derived suppressor cells enhance the expression of melanoma-associated antigen A4 in a Lewis lung cancer murine model. Oncology Letters, 2016, 11, 809-816.	0.8	11
434	Myeloid-derived suppressor cells: The green light for myeloma immune escape. Blood Reviews, 2016, 30, 341-348.	2.8	105
435	A phase I study of recombinant (r) vaccinia-CEA(6D)-TRICOM and rFowlpox-CEA(6D)-TRICOM vaccines with GM-CSF and IFN-Î-2b in patients with CEA-expressing carcinomas. Cancer Immunology, Immunotherapy, 2016, 65, 1353-1364.	2.0	31
436	Targeting the Bone Marrow Microenvironment. Cancer Treatment and Research, 2016, 169, 63-102.	0.2	12

#	ARTICLE	IF	CITATIONS
437	Myeloid cells as orchestrators of the tumor microenvironment: novel targets for nanoparticular cancer therapy. <i>Nanomedicine</i> , 2016, 11, 2735-2751.	1.7	18
438	Regulation of myeloid cells by activated T cells determines the efficacy of PD-1 blockade. <i>OncolImmunology</i> , 2016, 5, e1232222.	2.1	48
439	Distinct transcriptional changes in non-small cell lung cancer patients associated with multi-antigenic RNAActive® CV9201 immunotherapy. <i>OncolImmunology</i> , 2016, 5, e1249560.	2.1	18
440	Detection of inflammatory cell function using ¹³ C magnetic resonance spectroscopy of hyperpolarized [6- ¹³ C]-arginine. <i>Scientific Reports</i> , 2016, 6, 31397.	1.6	24
441	Inhibiting MDSC differentiation from bone marrow with phytochemical polyacetylenes drastically impairs tumor metastasis. <i>Scientific Reports</i> , 2016, 6, 36663.	1.6	29
442	Enhanced Survival with Implantable Scaffolds That Capture Metastatic Breast Cancer Cells <i>In Vivo</i> . <i>Cancer Research</i> , 2016, 76, 5209-5218.	0.4	86
443	Tumor-Associated Macrophages and Myeloid-Derived Suppressor Cells as Immunosuppressive Mechanism in Ovarian Cancer Patients: Progress and Challenges. <i>International Reviews of Immunology</i> , 2016, 35, 372-385.	1.5	31
444	The effect of cyclophosphamide on the immune system: implications for clinical cancer therapy. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 78, 661-671.	1.1	297
445	Identification of CD4 ⁺ CD25 ⁺ CD127 ⁺ regulatory T cells and CD14 ⁺ HLA-DR ^{low} /low myeloid-derived suppressor cells and their roles in the prognosis of breast cancer. <i>Biomedical Reports</i> , 2016, 5, 208-212.	0.9	32
446	Immune Suppressive Myeloid-Derived Suppressor Cells in Cancer. , 2016, , 512-525.		3
447	Immunological Consequences of Epithelial-Mesenchymal Transition in Tumor Progression. <i>Journal of Immunology</i> , 2016, 197, 691-698.	0.4	75
448	Doxorubicin resistant cancer cells activate myeloid-derived suppressor cells by releasing PGE2. <i>Scientific Reports</i> , 2016, 6, 23824.	1.6	58
449	Cryo-thermal therapy elicits potent anti-tumor immunity by inducing extracellular Hsp70-dependent MDSC differentiation. <i>Scientific Reports</i> , 2016, 6, 27136.	1.6	46
450	One microenvironment does not fit all: heterogeneity beyond cancer cells. <i>Cancer and Metastasis Reviews</i> , 2016, 35, 601-629.	2.7	58
451	Lectin-type oxidized LDL receptor-1 distinguishes population of human polymorphonuclear myeloid-derived suppressor cells in cancer patients. <i>Science Immunology</i> , 2016, 1, .	5.6	560
452	Splenectomy suppresses growth and metastasis of hepatocellular carcinoma through decreasing myeloid-derived suppressor cells in vivo. <i>Journal of Huazhong University of Science and Technology [Medical Sciences]</i> , 2016, 36, 667-676.	1.0	10
453	Role of the Microenvironment in Liver Metastasis: From Pre- to Prometastatic Niches. <i>Clinical Cancer Research</i> , 2016, 22, 5971-5982.	3.2	206
454	Circulating CD ¹⁴ ⁺ HLA-DR ^{low} myeloid-derived suppressor cells in leukemia patients with allogeneic hematopoietic stem cell transplantation: novel clinical potential strategies for the prevention and cellular therapy of graft-versus-host disease. <i>Cancer Medicine</i> , 2016, 5, 1654-1669.	1.3	30

#	ARTICLE	IF	CITATIONS
455	mTOR inhibitors effects on regulatory T cells and on dendritic cells. Journal of Translational Medicine, 2016, 14, 152.	1.8	57
456	Curdlan blocks the immune suppression by myeloid-derived suppressor cells and reduces tumor burden. Immunologic Research, 2016, 64, 931-939.	1.3	24
457	Expansion of a BDCA1+CD14+ Myeloid Cell Population in Melanoma Patients May Attenuate the Efficacy of Dendritic Cell Vaccines. Cancer Research, 2016, 76, 4332-4346.	0.4	93
458	CXCR2 Inhibition Profoundly Suppresses Metastases and Augments Immunotherapy in Pancreatic Ductal Adenocarcinoma. Cancer Cell, 2016, 29, 832-845.	7.7	645
459	Trim33/Tif1 ^{hi} is involved in late stages of granulomonopoiesis in mice. Experimental Hematology, 2016, 44, 727-739.e6.	0.2	13
460	A clinical and biological perspective of human myeloid-derived suppressor cells in cancer. Cellular and Molecular Life Sciences, 2016, 73, 4043-4061.	2.4	55
461	Yeast-Derived Particulate β -Glucan Treatment Subverts the Suppression of Myeloid-Derived Suppressor Cells (MDSC) by Inducing Polymorphonuclear MDSC Apoptosis and Monocytic MDSC Differentiation to APC in Cancer. Journal of Immunology, 2016, 196, 2167-2180.	0.4	86
462	Circulating Myeloid-Derived Suppressor Cells Predict Differentiated Thyroid Cancer Diagnosis and Extent. Thyroid, 2016, 26, 381-389.	2.4	58
463	Neutralization of Tumor Acidity Improves Antitumor Responses to Immunotherapy. Cancer Research, 2016, 76, 1381-1390.	0.4	451
464	Toward harmonized phenotyping of human myeloid-derived suppressor cells by flow cytometry: results from an interim study. Cancer Immunology, Immunotherapy, 2016, 65, 161-169.	2.0	175
465	Phagocyte function decreases after high-dose treatment with melphalan and autologous stem cell transplantation in patients with multiple myeloma. Experimental Hematology, 2016, 44, 342-351.e5.	0.2	4
466	Elevated levels of polymorphonuclear myeloid-derived suppressor cells in patients with glioblastoma highly express S100A8/9 and arginase and suppress T cell function. Neuro-Oncology, 2016, 18, 1253-1264.	0.6	119
468	Inflammatory Cells in Tumor Microenvironment. , 2016, , 27-50.		0
469	Myeloid-Derived Suppressor Cells Express Bruton's Tyrosine Kinase and Can Be Depleted in Tumor-Bearing Hosts by Ibrutinib Treatment. Cancer Research, 2016, 76, 2125-2136.	0.4	150
470	Enhancing T cell therapy by overcoming the immunosuppressive tumor microenvironment. Seminars in Immunology, 2016, 28, 54-63.	2.7	47
471	Neural innervation stimulates splenic TFF2 to arrest myeloid cell expansion and cancer. Nature Communications, 2016, 7, 10517.	5.8	86
472	The Role of Microenvironment in the Control of Tumor Angiogenesis. , 2016, , .		3
473	Targeting Suppressive Myeloid Cells Potentiates Checkpoint Inhibitors to Control Spontaneous Neuroblastoma. Clinical Cancer Research, 2016, 22, 3849-3859.	3.2	109

#	ARTICLE	IF	CITATIONS
474	Have lessons from past failures brought us closer to the success of immunotherapy in metastatic pancreatic cancer?. <i>Oncolmunology</i> , 2016, 5, e1112942.	2.1	19
475	Targeting myeloid-derived suppressor cells with colony stimulating factor-1 receptor blockade can reverse immune resistance to immunotherapy in indoleamine 2,3-dioxygenase-expressing tumors. <i>EBioMedicine</i> , 2016, 6, 50-58.	2.7	113
476	A novel multi-drug metronomic chemotherapy significantly delays tumor growth in mice. <i>Journal of Translational Medicine</i> , 2016, 14, 58.	1.8	18
477	The Microenvironment of Lung Cancer and Therapeutic Implications. <i>Advances in Experimental Medicine and Biology</i> , 2016, 890, 75-110.	0.8	96
478	Systemic Immune Activity Predicts Overall Survival in Treatment-Naïve Patients with Metastatic Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 2565-2574.	3.2	80
479	A randomized phase II clinical trial of personalized peptide vaccination with metronomic low-dose cyclophosphamide in patients with metastatic castration-resistant prostate cancer. <i>Cancer Immunology, Immunotherapy</i> , 2016, 65, 151-160.	2.0	57
480	MDSCs in cancer: Conceiving new prognostic and therapeutic targets. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2016, 1865, 35-48.	3.3	68
481	Immunosuppressive cells in tumor immune escape and metastasis. <i>Journal of Molecular Medicine</i> , 2016, 94, 509-522.	1.7	270
482	TNF- α -mediated microRNA-136 induces differentiation of myeloid cells by targeting NFIA. <i>Journal of Leukocyte Biology</i> , 2016, 99, 301-310.	1.5	13
483	New insights into myeloid-derived suppressor cells and their roles in feto-maternal immune cross-talk. <i>Journal of Reproductive Immunology</i> , 2016, 113, 35-41.	0.8	35
484	The immunobiology of myeloid-derived suppressor cells in cancer. <i>Tumor Biology</i> , 2016, 37, 1387-1406.	0.8	83
485	Targeting the tumor microenvironment to improve natural killer cell-based immunotherapies: On being in the right place at the right time, with resilience. <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 607-611.	1.4	38
486	Exosomes miR-126a released from MDSC induced by DOX treatment promotes lung metastasis. <i>Oncogene</i> , 2017, 36, 639-651.	2.6	162
487	Immunomodulatory Activity of VEGF in Cancer. <i>International Review of Cell and Molecular Biology</i> , 2017, 330, 295-342.	1.6	153
488	Management of Prostate Cancer. , 2017, , .		5
489	Identification of inhibitors of myeloid-derived suppressor cells activity through phenotypic chemical screening. <i>Oncolmunology</i> , 2017, 6, e1258503.	2.1	12
490	Breast Cancer Immunology and Immunotherapy. <i>International Review of Cell and Molecular Biology</i> , 2017, 331, 1-53.	1.6	47
491	A review of the importance of immune responses in luminal B breast cancer. <i>Oncolmunology</i> , 2017, 6, e1282590.	2.1	5

#	ARTICLE	IF	CITATIONS
492	Expansion of myeloid-derived suppressor cells with aging in the bone marrow of mice through a NF- κ B-dependent mechanism. <i>Aging Cell</i> , 2017, 16, 480-487.	3.0	80
493	The innate and adaptive infiltrating immune systems as targets for breast cancer immunotherapy. <i>Endocrine-Related Cancer</i> , 2017, 24, R123-R144.	1.6	64
495	Myeloid cells in circulation and tumor microenvironment of breast cancer patients. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 753-764.	2.0	63
496	Radiotherapy in the age of cancer immunology: Current concepts and future developments. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 112, 1-10.	2.0	19
498	IFN- γ -based treatment of patients with chronic HCV show increased levels of cells with myeloid-derived suppressor cell phenotype and of IDO and NOS. <i>Immunopharmacology and Immunotoxicology</i> , 2017, 39, 188-198.	1.1	6
499	CXCL1 Is Critical for Premetastatic Niche Formation and Metastasis in Colorectal Cancer. <i>Cancer Research</i> , 2017, 77, 3655-3665.	0.4	243
500	T-cell programming in pancreatic adenocarcinoma: a review. <i>Cancer Gene Therapy</i> , 2017, 24, 106-113.	2.2	45
501	Myeloid-derived suppressor cells and their role in pancreatic cancer. <i>Cancer Gene Therapy</i> , 2017, 24, 100-105.	2.2	71
502	Immunologic Response Elicited in Breast Cancer Patients Receiving a NeuGcGM3-based Vaccine as Adjuvant Therapy. <i>Journal of Immunotherapy</i> , 2017, 40, 289-301.	1.2	8
503	Quantitative cell-free circulating EGFR mutation concentration is correlated with tumor burden in advanced NSCLC patients. <i>Lung Cancer</i> , 2017, 109, 124-127.	0.9	27
504	Clinical development of immunotherapy for prostate cancer. <i>International Journal of Urology</i> , 2017, 24, 675-680.	0.5	6
505	STING signaling in tumorigenesis and cancer therapy: A friend or foe?. <i>Cancer Letters</i> , 2017, 402, 203-212.	3.2	50
506	Myeloid-derived suppressor cells "a new therapeutic target to overcome resistance to cancer immunotherapy. <i>Journal of Leukocyte Biology</i> , 2017, 102, 727-740.	1.5	88
507	Immune Correlates of GM-CSF and Melanoma Peptide Vaccination in a Randomized Trial for the Adjuvant Therapy of Resected High-Risk Melanoma (E4697). <i>Clinical Cancer Research</i> , 2017, 23, 5034-5043.	3.2	34
508	C-C Chemokine Receptor Type 2 "Dependent Migration of Myeloid-Derived Suppressor Cells in Protection of Islet Transplants. <i>Transplantation</i> , 2017, 101, 1793-1800.	0.5	31
509	Unleashing the immune response against childhood solid cancers. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26548.	0.8	6
510	CAR T-cell therapy for pancreatic cancer. <i>Journal of Surgical Oncology</i> , 2017, 116, 63-74.	0.8	69
511	Lung cancer and β -glucans: review of potential therapeutic applications. <i>Investigational New Drugs</i> , 2017, 35, 509-517.	1.2	25

#	ARTICLE	IF	CITATIONS
512	Suppression of T cells by myeloid-derived suppressor cells in cancer. <i>Human Immunology</i> , 2017, 78, 113-119.	1.2	62
513	Kinetics of Myeloid-Derived Suppressor Cell Frequency and Function during Simian Immunodeficiency Virus Infection, Combination Antiretroviral Therapy, and Treatment Interruption. <i>Journal of Immunology</i> , 2017, 198, 757-766.	0.4	23
514	The novel roles of stromal fibroblasts in metronomic chemotherapy: Focusing on cancer stemness and immunity. <i>Journal of Cancer Research and Practice</i> , 2017, 4, 123-126.	0.2	0
516	Dual negative roles of C/EBP β in the expansion and pro-tumor functions of MDSCs. <i>Scientific Reports</i> , 2017, 7, 14048.	1.6	29
517	Cancer Immunotherapy Getting Brainy: Visualizing the Distinctive CNS Metastatic Niche to Illuminate Therapeutic Resistance. <i>Drug Resistance Updates</i> , 2017, 33-35, 23-35.	6.5	16
518	MMP-9-cleaved osteopontin isoform mediates tumor immune escape by inducing expansion of myeloid-derived suppressor cells. <i>Biochemical and Biophysical Research Communications</i> , 2017, 493, 1478-1484.	1.0	33
519	Immunological efficacy of herbal medicines in prostate cancer patients treated by personalized peptide vaccine. <i>Cancer Science</i> , 2017, 108, 2326-2332.	1.7	18
520	Immunotherapy for Breast Cancer: Current and Future Strategies. <i>Current Surgery Reports</i> , 2017, 5, 1.	0.4	31
521	Tumor-associated neutrophils induce apoptosis of non-activated CD8 T-cells in a TNF α and NO-dependent mechanism, promoting a tumor-supportive environment. <i>Oncolmmunology</i> , 2017, 6, e1356965.	2.1	103
522	Increased Percentage of mo-MDSCs in Human Peripheral Blood May Be a Potential Indicator in the Diagnosis of Breast Cancer. <i>Oncology Research and Treatment</i> , 2017, 40, 603-608.	0.8	6
523	Circulating myeloid-derived suppressor cells increase in patients undergoing neo-adjuvant chemotherapy for breast cancer. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 1437-1447.	2.0	58
524	Myeloid suppressor cells in cancer and autoimmunity. <i>Journal of Autoimmunity</i> , 2017, 85, 117-125.	3.0	154
525	Acid-sensitive lipidated doxorubicin prodrug entrapped in nanoemulsion impairs lung tumor metastasis in a breast cancer model. <i>Nanomedicine</i> , 2017, 12, 1751-1765.	1.7	29
526	Myeloid-derived suppressor cells are increased and correlated with type 2 immune responses, malnutrition, inflammation, and poor prognosis in patients with breast cancer. <i>Oncology Letters</i> , 2017, 14, 1766-1774.	0.8	109
527	Cancer-promoting mechanisms of tumor-associated neutrophils. <i>American Journal of Surgery</i> , 2017, 214, 938-944.	0.9	95
528	Newly Characterized Murine Undifferentiated Sarcoma Models Sensitive to Virotherapy with Oncolytic HSV-1 M002. <i>Molecular Therapy - Oncolytics</i> , 2017, 7, 27-36.	2.0	13
529	Targeting interleukin-6 to relieve immunosuppression in tumor microenvironment. <i>Tumor Biology</i> , 2017, 39, 101042831771244.	0.8	55
530	Immunotherapy with <i>Listeria</i> reduces metastatic breast cancer in young and old mice through different mechanisms. <i>Oncolmmunology</i> , 2017, 6, e1342025.	2.1	26

#	ARTICLE	IF	CITATIONS
531	Postoperative Adjuvant Therapy for Resectable Pancreatic Cancer With Gemcitabine and Adoptive Immunotherapy. <i>Pancreas</i> , 2017, 46, 994-1002.	0.5	21
532	Chemotherapeutic agent-mediated elimination of myeloid-derived suppressor cells. <i>Oncolimmunology</i> , 2017, 6, e1331807.	2.1	106
533	Granulocytic Myeloid-Derived Suppressor Cells Increased in Early Phases of Primary HIV Infection Depending on TRAIL Plasma Level. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 74, 575-582.	0.9	25
534	Phenotypically resembling myeloid derived suppressor cells are increased in children with HIV and exposed/infected with <i>Mycobacterium tuberculosis</i> . <i>European Journal of Immunology</i> , 2017, 47, 107-118.	1.6	27
535	Myeloid-Derived Suppressor Cell Subset Accumulation in Renal Cell Carcinoma Parenchyma Is Associated with Intratumoral Expression of IL1 β , IL8, CXCL5, and Mip-1 α . <i>Clinical Cancer Research</i> , 2017, 23, 2346-2355.	3.2	148
536	Hepatic carcinoma-associated fibroblasts enhance immune suppression by facilitating the generation of myeloid-derived suppressor cells. <i>Oncogene</i> , 2017, 36, 1090-1101.	2.6	127
537	Inflammation-induced myeloid-derived suppressor cells associated with squamous cell carcinoma of the head and neck. <i>Head and Neck</i> , 2017, 39, 347-355.	0.9	37
538	No Evidence That Genetic Variation in the Myeloid-Derived Suppressor Cell Pathway Influences Ovarian Cancer Survival. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017, 26, 420-424.	1.1	3
539	HLA-C promotes myeloid-derived suppressor cell accumulation and suppressive activity during human pregnancy through engagement of the receptor ILT4. <i>European Journal of Immunology</i> , 2017, 47, 374-384.	1.6	83
540	Inhibition of IL-18-mediated myeloid derived suppressor cell accumulation enhances anti-PD1 efficacy against osteosarcoma cancer. <i>Journal of Bone Oncology</i> , 2017, 9, 59-64.	1.0	32
541	Tumor Immune Microenvironment in Cancer Progression and Cancer Therapy. <i>Advances in Experimental Medicine and Biology</i> , 2017, , .	0.8	9
542	Targeting Myeloid-Derived Suppressor Cells in Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2017, 1036, 105-128.	0.8	49
543	Multiple Myeloma and the immune microenvironment. <i>Current Cancer Drug Targets</i> , 2017, 17, 1-1.	0.8	59
544	IL-17 and VEGF are increased and correlated to systemic inflammation, immune suppression, and malnutrition in patients with breast cancer. <i>European Journal of Inflammation</i> , 2017, 15, 219-228.	0.2	10
545	Complement C3-dependent uptake of targeted liposomes into human macrophages, B cells, dendritic cells, neutrophils, and MDSCs. <i>International Journal of Nanomedicine</i> , 2017, Volume 12, 5149-5161.	3.3	22
546	Arachidonic Acid Metabolite as a Novel Therapeutic Target in Breast Cancer Metastasis. <i>International Journal of Molecular Sciences</i> , 2017, 18, 2661.	1.8	61
547	Cancer Immunotherapy—An Emerging Field That Bridges Oncology and Immunology Research. , 2017, , 357-394.		1
548	Human Tumor-Infiltrating Myeloid Cells: Phenotypic and Functional Diversity. <i>Frontiers in Immunology</i> , 2017, 8, 86.	2.2	167

#	ARTICLE	IF	CITATIONS
549	Differential Phenotypes of Myeloid-Derived Suppressor and T Regulatory Cells and Cytokine Levels in Amnesic Mild Cognitive Impairment Subjects Compared to Mild Alzheimer Diseased Patients. <i>Frontiers in Immunology</i> , 2017, 8, 783.	2.2	54
550	Recent Successes and Future Directions in Immunotherapy of Cutaneous Melanoma. <i>Frontiers in Immunology</i> , 2017, 8, 1617.	2.2	43
551	Comparison of Myeloid Cells in Circulation and in the Tumor Microenvironment of Patients with Colorectal and Breast Cancers. <i>Journal of Immunology Research</i> , 2017, 2017, 1-8.	0.9	10
552	Decreased expression of the $\alpha 2$ integrin on tumor cells is associated with a reduction in liver metastasis of colorectal cancer in mice. <i>BMC Cancer</i> , 2017, 17, 827.	1.1	29
553	Ex vivo expanded natural killer cells from breast cancer patients and healthy donors are highly cytotoxic against breast cancer cell lines and patient-derived tumours. <i>Breast Cancer Research</i> , 2017, 19, 76.	2.2	59
554	Highlights of the 31st annual meeting of the Society for Immunotherapy of Cancer (SITC), 2016. , 2017, 5, 55.		5
555	On the origin of myeloid-derived suppressor cells. <i>Oncotarget</i> , 2017, 8, 3649-3665.	0.8	156
556	Inhibiting HSP90 prevents the induction of myeloid-derived suppressor cells by melanoma cells. <i>Cellular Immunology</i> , 2018, 327, 68-76.	1.4	10
557	Arginase-1 is neither constitutively expressed in nor required for myeloid-derived suppressor cell-mediated inhibition of T cell proliferation. <i>European Journal of Immunology</i> , 2018, 48, 1046-1058.	1.6	45
558	Myeloid-derived suppressor cells in lymphoma: The good, the bad and the ugly. <i>Blood Reviews</i> , 2018, 32, 490-498.	2.8	29
559	Sarcomaâ€‘The standard-bearer in cancer discovery. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 126, 1-5.	2.0	39
560	Myeloid-derived suppressors cells (MDSC) correlate with clinicopathologic factors and pathologic complete response (pCR) in patients with urothelial carcinoma (UC) undergoing cystectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 405-412.	0.8	40
561	Phenotypic and functional alterations of myeloid-derived suppressor cells during the disease course of multiple sclerosis. <i>Immunology and Cell Biology</i> , 2018, 96, 820-830.	1.0	38
562	Blockade of CCL2 enhances immunotherapeutic effect of anti-PD1 in lung cancer. <i>Journal of Bone Oncology</i> , 2018, 11, 27-32.	1.0	63
563	Chemotherapy alters the increased numbers of myeloid-derived suppressor and regulatory T cells in children with acute lymphoblastic leukemia. <i>Immunopharmacology and Immunotoxicology</i> , 2018, 40, 158-167.	1.1	29
564	Myeloid-derived suppressor cells coming of age. <i>Nature Immunology</i> , 2018, 19, 108-119.	7.0	1,285
565	The breast tumor microenvironment: role in cancer development, progression and response to therapy. <i>Expert Review of Molecular Diagnostics</i> , 2018, 18, 227-243.	1.5	115
566	Transcriptional characterization of immunological infiltrates and their relation with glioblastoma patients overall survival. <i>Oncolmmunology</i> , 2018, 7, e1431083.	2.1	28

#	ARTICLE	IF	CITATIONS
567	Immunologic Approaches to Breast Cancer Therapy. , 2018, , 924-933.e4.		2
568	Neutrophils and PMN-MDSC: Their biological role and interaction with stromal cells. <i>Seminars in Immunology</i> , 2018, 35, 19-28.	2.7	230
569	Blockade of CCR5-mediated myeloid derived suppressor cell accumulation enhances anti-PD1 efficacy in gastric cancer. <i>Immunopharmacology and Immunotoxicology</i> , 2018, 40, 91-97.	1.1	30
570	Immature myeloid cells in the tumor microenvironment: Implications for immunotherapy. <i>Clinical Immunology</i> , 2018, 189, 34-42.	1.4	37
571	Humoral and Cellular Immune Dysregulation and Lung Cancer. , 2018, , 137-142.e3.		1
572	Synthetic immune niches for cancer immunotherapy. <i>Nature Reviews Immunology</i> , 2018, 18, 212-219.	10.6	141
573	Major surgery diminishes systemic arginine availability and suppresses nitric oxide response to feeding in patients with early stage breast cancer. <i>Clinical Nutrition</i> , 2018, 37, 1645-1653.	2.3	9
574	Triple negative breast cancer " prognostic role of immune-related factors: a systematic review. <i>Acta Oncologica</i> , 2018, 57, 74-82.	0.8	93
575	High numbers of myeloid derived suppressor cells in peripheral blood and ascitic fluid of cirrhotic and HCC patients. <i>Immunological Investigations</i> , 2018, 47, 169-180.	1.0	40
576	The role of STAT3 in leading the crosstalk between human cancers and the immune system. <i>Cancer Letters</i> , 2018, 415, 117-128.	3.2	237
577	CD14+HLA-DR ^{low} MDSCs are elevated in the periphery of early-stage breast cancer patients and suppress autologous T cell proliferation. <i>Breast Cancer Research and Treatment</i> , 2018, 168, 401-411.	1.1	22
578	Conditioned media from the renal cell carcinoma cell line 786.O drives human blood monocytes to a monocytic myeloid-derived suppressor cell phenotype. <i>Cellular Immunology</i> , 2018, 323, 49-58.	1.4	14
579	Breast cancer genomics and immuno-oncological markers to guide immune therapies. <i>Seminars in Cancer Biology</i> , 2018, 52, 178-188.	4.3	111
580	The Yin and Yang of Myeloid Derived Suppressor Cells. <i>Frontiers in Immunology</i> , 2018, 9, 2776.	2.2	58
581	Immune regulation and anti-cancer activity by lipid inflammatory mediators. <i>International Immunopharmacology</i> , 2018, 65, 580-592.	1.7	29
582	Crosstalk Between PD-1/PD-L1 Blockade and Its Combinatorial Therapies in Tumor Immune Microenvironment: A Focus on HNSCC. <i>Frontiers in Oncology</i> , 2018, 8, 532.	1.3	27
583	Long term impact of CTLA4 blockade immunotherapy on regulatory and effector immune responses in patients with melanoma. <i>Journal of Translational Medicine</i> , 2018, 16, 184.	1.8	36
584	Immune-Phenotyping and Transcriptomic Profiling of Peripheral Blood Mononuclear Cells From Patients With Breast Cancer: Identification of a 3 Gene Signature Which Predicts Relapse of Triple Negative Breast Cancer. <i>Frontiers in Immunology</i> , 2018, 9, 2028.	2.2	36

#	ARTICLE	IF	CITATIONS
585	Immunological Correlates of Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma. <i>Targeted Oncology</i> , 2018, 13, 599-609.	1.7	22
586	Improved Cancer Immunochemotherapy via Optimal Co-delivery of Chemotherapeutic and Immunomodulatory Agents. <i>Molecular Pharmaceutics</i> , 2018, 15, 5162-5173.	2.3	20
587	Molecular imaging to enlighten cancer immunotherapies and underlying involved processes. <i>Cancer Treatment Reviews</i> , 2018, 70, 232-244.	3.4	36
588	NOTCH Signaling in T-Cell-Mediated Anti-Tumor Immunity and T-Cell-Based Immunotherapies. <i>Frontiers in Immunology</i> , 2018, 9, 1718.	2.2	47
589	Predicting the response to neoadjuvant therapy for early-stage breast cancer: tumor-, blood-, and imaging-related biomarkers. <i>Cancer Management and Research</i> , 2018, Volume 10, 4333-4347.	0.9	37
590	Tumor-derived granulocyte colony-stimulating factor diminishes efficacy of breast tumor cell vaccines. <i>Breast Cancer Research</i> , 2018, 20, 126.	2.2	25
591	Consumption of β -glucans to spice up T cell treatment of tumors: a review. <i>Expert Opinion on Biological Therapy</i> , 2018, 18, 1023-1040.	1.4	35
592	The Interplay between Circulating Tumor Cells and the Immune System: From Immune Escape to Cancer Immunotherapy. <i>Diagnostics</i> , 2018, 8, 59.	1.3	57
593	A new procedure to analyze polymorphonuclear myeloid derived suppressor cells in cryopreserved samples cells by flow cytometry. <i>PLoS ONE</i> , 2018, 13, e0202920.	1.1	7
594	Cancer-induced systemic myeloid dysfunction: Implications for treatment and a novel nanoparticle approach for its correction. <i>Seminars in Oncology</i> , 2018, 45, 84-94.	0.8	10
595	Cancer-related circulating and tumor-associated neutrophils " subtypes, sources and function. <i>FEBS Journal</i> , 2018, 285, 4316-4342.	2.2	156
596	Prediction of non-linear pharmacokinetics in humans of an antibody-drug conjugate (ADC) when evaluation of higher doses in animals is limited by tolerability: Case study with an anti-CD33 ADC. <i>MAbs</i> , 2018, 10, 738-750.	2.6	3
597	Neutrophils as myeloid-derived suppressor cells. <i>European Journal of Clinical Investigation</i> , 2018, 48, e12989.	1.7	60
598	Blood-based analyses of cancer: Circulating myeloid-derived suppressor cells " is a new era coming?. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2018, 55, 376-407.	2.7	16
599	Tracking the fate of adoptively transferred myeloid-derived suppressor cells in the primary breast tumor microenvironment. <i>PLoS ONE</i> , 2018, 13, e0196040.	1.1	11
600	Circulating and tumor-infiltrating myeloid-derived suppressor cells in cervical carcinoma patients. <i>Oncology Letters</i> , 2018, 15, 9507-9515.	0.8	24
601	The Prokineticins: Neuromodulators and Mediators of Inflammation and Myeloid Cell-Dependent Angiogenesis. <i>Physiological Reviews</i> , 2018, 98, 1055-1082.	13.1	65
602	Prognostic utility of baseline neutrophil-to-lymphocyte ratio in patients receiving immune checkpoint inhibitors: a review and meta-analysis. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 955-965.	1.0	241

#	ARTICLE	IF	CITATIONS
603	Inhibiting Notch1 enhances immunotherapy efficacy in melanoma by preventing Notch1 dependent immune suppressive properties. <i>Cancer Letters</i> , 2018, 434, 144-151.	3.2	25
604	(α)-4-O-(4-O- β -D-glucopyranosylcaffeoyl) Quinic Acid Inhibits the Function of Myeloid-Derived Suppressor Cells to Enhance the Efficacy of Anti-PD1 against Colon Cancer. <i>Pharmaceutical Research</i> , 2018, 35, 183.	1.7	11
605	Targeting Myeloid-Derived Suppressor Cells to Bypass Tumor-Induced Immunosuppression. <i>Frontiers in Immunology</i> , 2018, 9, 398.	2.2	354
606	Hydrogen Sulfide Reduces Myeloid-Derived Suppressor Cell-Mediated Inflammatory Response in a Model of <i>Helicobacter hepaticus</i> -Induced Colitis. <i>Frontiers in Immunology</i> , 2018, 9, 499.	2.2	27
607	“Vessels in the Storm” Searching for Prognostic and Predictive Angiogenic Factors in Colorectal Cancer. <i>International Journal of Molecular Sciences</i> , 2018, 19, 299.	1.8	29
608	The hepatic pre-metastatic niche in pancreatic ductal adenocarcinoma. <i>Molecular Cancer</i> , 2018, 17, 95.	7.9	67
609	Enhanced Tumor Retention Effect by Click Chemistry for Improved Cancer Immunotherapy. <i>ACS Applied Materials & Interfaces</i> , 2018, 10, 17582-17593.	4.0	37
610	Monitoring the responsiveness of T and antigen presenting cell compartments in breast cancer patients is useful to predict clinical tumor response to neoadjuvant chemotherapy. <i>BMC Cancer</i> , 2018, 18, 77.	1.1	10
611	Adverse effects induced by diclofenac, ibuprofen, and paracetamol toxicity on immunological and biochemical parameters in Swiss albino mice. <i>Journal of Basic and Applied Zoology</i> , 2018, 79, .	0.4	22
612	The concept of oligometastases in colorectal cancer: from the clinical evidences to new therapeutic strategies. <i>Current Opinion in Oncology</i> , 2018, 30, 262-268.	1.1	15
613	Role of tumor microenvironment in cancer stem cell chemoresistance and recurrence. <i>International Journal of Biochemistry and Cell Biology</i> , 2018, 103, 115-124.	1.2	54
614	Myeloid-derived suppressor cells and their role in gynecological malignancies. <i>Tumor Biology</i> , 2018, 40, 101042831877648.	0.8	22
615	Treating the Intestine with Oral ApoA-I Mimetic Tg6F Reduces Tumor Burden in Mouse Models of Metastatic Lung Cancer. <i>Scientific Reports</i> , 2018, 8, 9032.	1.6	31
616	Cyclophosphamide with or without fluorouracil followed by subcutaneous or intravenous interleukin-2 use in solid tumors: A feasibility off-label experience. <i>Cytokine</i> , 2019, 113, 50-60.	1.4	5
617	Functional Diversity of Myeloid-Derived Suppressor Cells: The Multitasking Hydra of Cancer. <i>Journal of Immunology</i> , 2019, 203, 1095-1103.	0.4	19
618	The Complex Interaction between the Tumor Micro-Environment and Immune Checkpoints in Breast Cancer. <i>Cancers</i> , 2019, 11, 1205.	1.7	57
619	Regulation of Immunity in Breast Cancer. <i>Cancers</i> , 2019, 11, 1080.	1.7	43
620	<p>Mechanisms behind prometastatic changes induced by neoadjuvant chemotherapy in the breast cancer microenvironment</p>. <i>Breast Cancer: Targets and Therapy</i> , 2019, Volume 11, 209-219.	1.0	8

#	ARTICLE	IF	CITATIONS
621	<p>Effects of anesthetic technique and surgery on myeloid-derived suppressor cells and prognosis in women who underwent breast cancer surgery: a prospective study</p>. Cancer Management and Research, 2019, Volume 11, 5513-5522.	0.9	13
622	Dietary Flavonoids for Immunoregulation and Cancer: Food Design for Targeting Disease. Antioxidants, 2019, 8, 202.	2.2	63
623	Cancer-Derived Exosomes as Effectors of Key Inflammation-Related Players. Frontiers in Immunology, 2019, 10, 2103.	2.2	87
624	STAT3, a Master Regulator of Anti-Tumor Immune Response. Cancers, 2019, 11, 1280.	1.7	68
625	Targeting myeloid-derived suppressor cells in combination with primary mammary tumor resection reduces metastatic growth in the lungs. Breast Cancer Research, 2019, 21, 103.	2.2	55
626	A PD-L2-based immune marker signature helps to predict survival in resected pancreatic ductal adenocarcinoma. , 2019, 7, 233.		34
627	Patients with BRCA mutated ovarian cancer may have fewer circulating MDSC and more peripheral CD8+ T cells compared with women with BRCA wildâ€™type disease during the early disease course. Oncology Letters, 2019, 18, 3914-3924.	0.8	5
628	Impact of systemic therapy on circulating leukocyte populations in patients with metastatic breast cancer. Scientific Reports, 2019, 9, 13451.	1.6	21
629	Neutrophils as Suppressors of T Cell Proliferation: Does Age Matter?. Frontiers in Immunology, 2019, 10, 2144.	2.2	40
630	Metabolic crosstalk in the breast cancer microenvironment. European Journal of Cancer, 2019, 121, 154-171.	1.3	128
631	Tumor-Infiltrating Immunosuppressive Cells in Cancer-Cell Plasticity, Tumor Progression and Therapy Response. Cancer Microenvironment, 2019, 12, 119-132.	3.1	46
632	Myeloid-derived suppressor cells are bound and inhibited by anti-thymocyte globulin. Innate Immunity, 2019, 25, 46-59.	1.1	11
633	CXCL12/CXCR4 promotes inflammation-driven colorectal cancer progression through activation of RhoA signaling by sponging miR-133a-3p. Journal of Experimental and Clinical Cancer Research, 2019, 38, 32.	3.5	151
634	Elevated NLR May Be a Feature of Pediatric Brain Cancer Patients. Frontiers in Oncology, 2019, 9, 327.	1.3	15
635	Selectively hampered activation of lymph node-resident dendritic cells precedes profound T cell suppression and metastatic spread in the breast cancer sentinel lymph node. , 2019, 7, 133.		32
636	Neutrophil-to-Lymphocyte Ratio in Rectal Cancerâ€™Novel Biomarker of Tumor Immunogenicity During Radiotherapy or Confounding Variable?. International Journal of Molecular Sciences, 2019, 20, 2448.	1.8	33
637	Cell Adhesion Molecules and Their Roles and Regulation in the Immune and Tumor Microenvironment. Frontiers in Immunology, 2019, 10, 1078.	2.2	430
638	Identification of monocyte-like precursors of granulocytes in cancer as a mechanism for accumulation of PMN-MDSCs. Journal of Experimental Medicine, 2019, 216, 2150-2169.	4.2	85

#	ARTICLE	IF	CITATIONS
639	mTOR and Aging: An Old Fashioned Dress. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2774.	1.8	64
640	Frequency of Immune Cell Subtypes in Peripheral Blood Correlates With Outcome for Patients With Metastatic Breast Cancer Treated With High-Dose Chemotherapy. <i>Clinical Breast Cancer</i> , 2019, 19, 433-442.	1.1	5
641	A Phase I/II Trial of Cetuximab in Combination with Interleukin-12 Administered to Patients with Unresectable Primary or Recurrent Head and Neck Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , 2019, 25, 4955-4965.	3.2	30
642	Tumour-associated neutrophils in patients with cancer. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 601-620.	12.5	558
643	A β -1,3/1,6-glucan from <i>Durvillaea Antarctica</i> inhibits tumor progression in vivo as an immune stimulator. <i>Carbohydrate Polymers</i> , 2019, 222, 114993.	5.1	26
644	Targeting the tumor microenvironment in pancreatic ductal adenocarcinoma. <i>Expert Review of Anticancer Therapy</i> , 2019, 19, 473-482.	1.1	26
645	Gastric Tumorigenesis: Role of Inflammation and <i>Helicobacter pylori</i> . <i>Current Clinical Pathology</i> , 2019, , 3-23.	0.0	1
646	A Novel Paradigm Between Leukocytosis, G-CSF Secretion, Neutrophil-to-Lymphocyte Ratio, Myeloid-Derived Suppressor Cells, and Prognosis in Non-small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2019, 9, 295.	1.3	47
647	Beyond PD-1/PD-L1 Inhibition: What the Future Holds for Breast Cancer Immunotherapy. <i>Cancers</i> , 2019, 11, 628.	1.7	51
648	Consequences of EMT-Driven Changes in the Immune Microenvironment of Breast Cancer and Therapeutic Response of Cancer Cells. <i>Journal of Clinical Medicine</i> , 2019, 8, 642.	1.0	47
649	Immunological consequences of chemotherapy: Single drugs, combination therapies and nanoparticle-based treatments. <i>Journal of Controlled Release</i> , 2019, 305, 130-154.	4.8	40
650	Flavonoids: New Frontier for Immuno-Regulation and Breast Cancer Control. <i>Antioxidants</i> , 2019, 8, 103.	2.2	64
651	Aurora A Inhibition Eliminates Myeloid Cell-Mediated Immunosuppression and Enhances the Efficacy of Anti-PD-L1 Therapy in Breast Cancer. <i>Cancer Research</i> , 2019, 79, 3431-3444.	0.4	61
652	Phase I study of gene-mediated cytotoxic immunotherapy with AdV-tk as adjuvant to surgery and radiation for pediatric malignant glioma and recurrent ependymoma. <i>Neuro-Oncology</i> , 2019, 21, 537-546.	0.6	61
653	The transcriptional profile of circulating myeloid derived suppressor cells correlates with tumor development and progression in mouse. <i>Genes and Immunity</i> , 2019, 20, 589-598.	2.2	6
654	Regulation of Tumor-Associated Myeloid Cell Activity by CBP/EP300 Bromodomain Modulation of H3K27 Acetylation. <i>Cell Reports</i> , 2019, 27, 269-281.e4.	2.9	37
655	Harnessing the Immune System in HER2+ Disease. , 2019, , 213-230.		0
656	Increased circulating GrMyeloid-derived suppressor cells correlated with tumor burden and survival in locally advanced cervical cancer patient. <i>Journal of Cancer</i> , 2019, 10, 1341-1348.	1.2	22

#	ARTICLE	IF	CITATIONS
657	Nicotinamide Phosphoribosyltransferase Acts as a Metabolic Gate for Mobilization of Myeloid-Derived Suppressor Cells. <i>Cancer Research</i> , 2019, 79, 1938-1951.	0.4	58
658	Frequency and Implications of myeloid-derived suppressor cells and lymphocyte subsets in Egyptian patients with hepatitis C virus-related hepatocellular carcinoma. <i>Journal of Medical Virology</i> , 2019, 91, 1319-1328.	2.5	23
659	Activated neutrophils exert myeloid-derived suppressor cell activity damaging T cells beyond repair. <i>Blood Advances</i> , 2019, 3, 3562-3574.	2.5	75
660	Mediators of Inflammation-Driven Expansion, Trafficking, and Function of Tumor-Infiltrating MDSCs. <i>Cancer Immunology Research</i> , 2019, 7, 1687-1699.	1.6	33
661	Visualization and quantification of <i>in vivo</i> homing kinetics of myeloid-derived suppressor cells in primary and metastatic cancer. <i>Theranostics</i> , 2019, 9, 5869-5885.	4.6	31
662	Allies or Enemies? The Multifaceted Role of Myeloid Cells in the Tumor Microenvironment. <i>Frontiers in Immunology</i> , 2019, 10, 2746.	2.2	41
663	<i>Cancer Immunotherapy.</i> , 2019, , 231-250.		0
664	Needle-guided ablation of locally advanced pancreatic cancer: cytoreduction or immunomodulation by <i>in vivo</i> vaccination?. <i>Chinese Clinical Oncology</i> , 2019, 8, 61-61.	0.4	18
665	Safety and immune cell kinetics after donor natural killer cell infusion following haploidentical stem cell transplantation in children with recurrent neuroblastoma. <i>PLoS ONE</i> , 2019, 14, e0225998.	1.1	9
666	Prostaglandin E2/EP Signaling in the Tumor Microenvironment of Colorectal Cancer. <i>International Journal of Molecular Sciences</i> , 2019, 20, 6254.	1.8	105
667	Increased Adiposity Enhances the Accumulation of MDSCs in the Tumor Microenvironment and Adipose Tissue of Pancreatic Tumor-Bearing Mice and in Immune Organs of Tumor-Free Hosts. <i>Nutrients</i> , 2019, 11, 3012.	1.7	23
668	Serum levels of the chemokine CCL2 are elevated in malignant pleural mesothelioma patients. <i>BMC Cancer</i> , 2019, 19, 1204.	1.1	17
669	Stromal biology and therapy in pancreatic cancer: ready for clinical translation?. <i>Gut</i> , 2019, 68, 159-171.	6.1	246
670	Structural characterization of a polysaccharide from <i>Coreopsis tinctoria</i> Nutt. and its function to modify myeloid derived suppressor cells. <i>International Journal of Biological Macromolecules</i> , 2019, 126, 926-933.	3.6	19
671	T-cell-Secreted TNF α Induces Emergency Myelopoiesis and Myeloid-Derived Suppressor Cell Differentiation in Cancer. <i>Cancer Research</i> , 2019, 79, 346-359.	0.4	45
672	Targeting the crosstalk between cytokine-induced killer cells and myeloid-derived suppressor cells in hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2019, 70, 449-457.	1.8	102
673	Intratumoral delivery of antigen with complement C3-bound liposomes reduces tumor growth in mice. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2019, 18, 326-335.	1.7	14
674	Cellular Senescence: Aging, Cancer, and Injury. <i>Physiological Reviews</i> , 2019, 99, 1047-1078.	13.1	641

#	ARTICLE	IF	CITATIONS
675	NK Cells Expressing a Chimeric Activating Receptor Eliminate MDSCs and Rescue Impaired CAR-T Cell Activity against Solid Tumors. <i>Cancer Immunology Research</i> , 2019, 7, 363-375.	1.6	180
676	Virotherapy-recruited PMN-MDSC infiltration of mesothelioma blocks antitumor CTL by IL-10-mediated dendritic cell suppression. <i>OncImmunology</i> , 2019, 8, e1518672.	2.1	27
677	Circulating myeloid-derived suppressor cells: An independent prognostic factor in patients with breast cancer. <i>Journal of Cellular Physiology</i> , 2019, 234, 3515-3525.	2.0	62
678	FUT4 is involved in PD-1-related immunosuppression and leads to worse survival in patients with operable lung adenocarcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 65-76.	1.2	18
679	Prokineticins and their G protein-coupled receptors in health and disease. <i>Progress in Molecular Biology and Translational Science</i> , 2019, 161, 149-179.	0.9	25
680	TLR 7/8 agonist reverses oxaliplatin resistance in colorectal cancer via directing the myeloid-derived suppressor cells to tumoricidal M1-macrophages. <i>Cancer Letters</i> , 2020, 469, 173-185.	3.2	95
681	Myeloid immunosuppression and immune checkpoints in the tumor microenvironment. <i>Cellular and Molecular Immunology</i> , 2020, 17, 1-12.	4.8	273
682	The pan-therapeutic resistance of disseminated tumor cells: Role of phenotypic plasticity and the metastatic microenvironment. <i>Seminars in Cancer Biology</i> , 2020, 60, 138-147.	4.3	26
683	Phase 1b study of a small molecule antagonist of human chemokine (C-C motif) receptor 2 (PF-04136309) in combination with nab-paclitaxel/gemcitabine in first-line treatment of metastatic pancreatic ductal adenocarcinoma. <i>Investigational New Drugs</i> , 2020, 38, 800-811.	1.2	106
684	Prognostic value of neutrophil-to-lymphocyte ratio in older patients with head and neck cancer. <i>Journal of Geriatric Oncology</i> , 2020, 11, 417-422.	0.5	14
685	CD33+ Immature Myeloid Cells Critically Predict Recurrence in Advanced Gastric Cancer. <i>Journal of Surgical Research</i> , 2020, 245, 552-563.	0.8	6
686	Granulocytic myeloid-derived suppressor cells correlate with outcomes undergoing neoadjuvant chemotherapy for bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 5.e17-5.e23.	0.8	2
687	Tumor-infiltrating and circulating granulocytic myeloid-derived suppressor cells correlate with disease activity and adverse clinical outcomes in mycosis fungoides. <i>Clinical and Translational Oncology</i> , 2020, 22, 1059-1066.	1.2	10
688	Liver Tropism in Cancer: The Hepatic Metastatic Niche. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2020, 10, a037259.	2.9	35
689	Crosstalk between myeloid-derived suppressor cells and the immune system in prostate cancer. <i>Journal of Leukocyte Biology</i> , 2020, 107, 43-56.	1.5	28
690	Clinical relevance of systemic monocytic-MDSCs in patients with metastatic breast cancer. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 435-448.	2.0	44
691	Lymphocyte-Monocyte Ratio Significantly Predicts Recurrence in Papillary Thyroid Cancer. <i>Journal of Surgical Research</i> , 2020, 246, 535-543.	0.8	34
692	Chemokines and their receptors promoting the recruitment of myeloid-derived suppressor cells into the tumor. <i>Molecular Immunology</i> , 2020, 117, 201-215.	1.0	116

#	ARTICLE	IF	CITATIONS
693	Premetastatic niches, exosomes and circulating tumor cells: Early mechanisms of tumor dissemination and the relation to surgery. <i>International Journal of Cancer</i> , 2020, 146, 3244-3255.	2.3	20
694	Role of telomerase in the tumour microenvironment. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2020, 47, 357-364.	0.9	17
695	Myeloid Cells Orchestrate Systemic Immunosuppression, Impairing the Efficacy of Immunotherapy against HPV+ Cancers. <i>Cancer Immunology Research</i> , 2020, 8, 131-145.	1.6	21
696	Platinum Derivatives Effects on Anticancer Immune Response. <i>Biomolecules</i> , 2020, 10, 13.	1.8	55
697	The Immune Microenvironment in Pancreatic Cancer. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7307.	1.8	133
698	Inhibitory effect of ginsenoside Rg3 on cancer stemness and mesenchymal transition in breast cancer via regulation of myeloid-derived suppressor cells. <i>PLoS ONE</i> , 2020, 15, e0240533.	1.1	21
699	A Perspective on Therapeutic Pan-Resistance in Metastatic Cancer. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7304.	1.8	11
700	Stem cell factor produced by tumor cells expands myeloid-derived suppressor cells in mice. <i>Scientific Reports</i> , 2020, 10, 11257.	1.6	14
701	Detection of response to tumor microenvironmentâ€“targeted cellular immunotherapy using nano-radiomics. <i>Science Advances</i> , 2020, 6, eaba6156.	4.7	27
702	Osteopontin: A Key Regulator of Tumor Progression and Immunomodulation. <i>Cancers</i> , 2020, 12, 3379.	1.7	81
703	IGFLR1 as a Novel Prognostic Biomarker in Clear Cell Renal Cell Cancer Correlating With Immune Infiltrates. <i>Frontiers in Molecular Biosciences</i> , 2020, 7, 565173.	1.6	8
704	HOX Genes Family and Cancer: A Novel Role for Homeobox B9 in the Resistance to Anti-Angiogenic Therapies. <i>Cancers</i> , 2020, 12, 3299.	1.7	14
705	Cross-talk between myeloid-derived suppressor cells and Mucin1 in breast cancer vaccination: On the verge of a breakthrough. <i>Life Sciences</i> , 2020, 258, 118128.	2.0	12
706	Combinatorial drug therapy in cancer - New insights. <i>Life Sciences</i> , 2020, 258, 118134.	2.0	31
707	Resistance to Anti-angiogenic Therapies: A Mechanism Depending on the Time of Exposure to the Drugs. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 584.	1.8	40
708	The New Era of Cancer Immunotherapy: Targeting Myeloid-Derived Suppressor Cells to Overcome Immune Evasion. <i>Frontiers in Immunology</i> , 2020, 11, 1680.	2.2	194
709	Role of Tumor-Associated Myeloid Cells in Breast Cancer. <i>Cells</i> , 2020, 9, 1785.	1.8	56
710	The immunology of renal cell carcinoma. <i>Nature Reviews Nephrology</i> , 2020, 16, 721-735.	4.1	229

#	ARTICLE	IF	CITATIONS
711	The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy. <i>Nature Reviews Cancer</i> , 2020, 20, 662-680.	12.8	860
712	Multidirectional Strategies for Targeted Delivery of Oncolytic Viruses by Tumor Infiltrating Immune Cells. <i>Pharmacological Research</i> , 2020, 161, 105094.	3.1	11
713	Poor dietary intake improved by total excision of oral cavity metastases in a patient with hepatocellular carcinoma and elevated myeloid-derived suppressor cells. <i>Hepatobiliary Surgery and Nutrition</i> , 2020, 9, 558-561.	0.7	1
714	Mechanisms of immune suppression by myeloid-derived suppressor cells: the role of interleukin-10 as a key immunoregulatory cytokine. <i>Open Biology</i> , 2020, 10, 200111.	1.5	58
715	Reactive Myelopoiesis Triggered by Lymphodepleting Chemotherapy Limits the Efficacy of Adoptive T Cell Therapy. <i>Molecular Therapy</i> , 2020, 28, 2252-2270.	3.7	29
716	High M-MDSC Percentage as a Negative Prognostic Factor in Chronic Lymphocytic Leukaemia. <i>Cancers</i> , 2020, 12, 2614.	1.7	16
717	miR-21a in exosomes from Lewis lung carcinoma cells accelerates tumor growth through targeting PDCD4 to enhance expansion of myeloid-derived suppressor cells. <i>Oncogene</i> , 2020, 39, 6354-6369.	2.6	23
718	The Great Debate at "Immunotherapy Bridge"™, Naples, December 5, 2019. , 2020, 8, e000921.		3
719	Granulocytic Myeloid-Derived Suppressor Cells as Negative Regulators of Anticancer Immunity. <i>Frontiers in Immunology</i> , 2020, 11, 1963.	2.2	41
720	Sympathetic nervous tone limits the development of myeloid-derived suppressor cells. <i>Science Immunology</i> , 2020, 5, .	5.6	13
721	Combination of thermally ablative focused ultrasound with gemcitabine controls breast cancer via adaptive immunity. , 2020, 8, e001008.		28
722	Lipid Metabolism and Cancer Immunotherapy: Immunosuppressive Myeloid Cells at the Crossroad. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5845.	1.8	51
723	Strategies to Improve Chimeric Antigen Receptor Therapies for Neuroblastoma. <i>Vaccines</i> , 2020, 8, 753.	2.1	7
724	NOX2-Derived Reactive Oxygen Species in Cancer. <i>Oxidative Medicine and Cellular Longevity</i> , 2020, 2020, 1-15.	1.9	25
725	Deep and Durable Response to Nivolumab and Temozolomide in Small-Cell Lung Cancer Associated With an Early Decrease in Myeloid-Derived Suppressor Cells. <i>Clinical Lung Cancer</i> , 2021, 22, e487-e497.	1.1	6
726	Sunitinib Treatment-elicited Distinct Tumor Microenvironment Dramatically Compensated the Reduction of Myeloid-derived Suppressor Cells. <i>In Vivo</i> , 2020, 34, 1141-1152.	0.6	6
727	Circulating and tumor-infiltrating arginase 1-expressing cells in gastric adenocarcinoma patients were mainly immature and monocytic Myeloid-derived suppressor cells. <i>Scientific Reports</i> , 2020, 10, 8056.	1.6	18
728	Regulation of the tumor immune microenvironment and vascular normalization in TNBC murine models by a novel peptide. <i>Oncolmmunology</i> , 2020, 9, 1760685.	2.1	11

#	ARTICLE	IF	CITATIONS
729	Reciprocal Signaling between Myeloid Derived Suppressor and Tumor Cells Enhances Cellular Motility and is Mediated by Structural Cues in the Microenvironment. <i>Advanced Biology</i> , 2020, 4, 2000049.	3.0	6
730	Apolipoprotein A-I Mimetic Peptide L-4F Suppresses Granulocytic-Myeloid-Derived Suppressor Cells in Mouse Pancreatic Cancer. <i>Frontiers in Pharmacology</i> , 2020, 11, 576.	1.6	15
731	CCL2/CCR2 signaling in cancer pathogenesis. <i>Cell Communication and Signaling</i> , 2020, 18, 82.	2.7	166
732	Novel Forms of Immunomodulation for Cancer Therapy. <i>Trends in Cancer</i> , 2020, 6, 518-532.	3.8	17
733	Using Preclinical Data to Design Combination Clinical Trials of Radiation Therapy and Immunotherapy. <i>Seminars in Radiation Oncology</i> , 2020, 30, 158-172.	1.0	10
734	Detecting Prostate Cancer Using Pattern Recognition Neural Networks With Flow Cytometry-Based Immunophenotyping in At-Risk Men. <i>Biomarker Insights</i> , 2020, 15, 117727192091332.	1.0	5
735	Baseline Splenic Volume as a Prognostic Biomarker of FOLFIRI Efficacy and a Surrogate Marker of MDSC Accumulation in Metastatic Colorectal Carcinoma. <i>Cancers</i> , 2020, 12, 1429.	1.7	7
736	Resistance Mechanisms to Anti-angiogenic Therapies in Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 221.	1.3	213
737	IMMUNEPOTENT CRP plus doxorubicin/cyclophosphamide chemotherapy remodel the tumor microenvironment in an air pouch triple-negative breast cancer murine model. <i>Biomedicine and Pharmacotherapy</i> , 2020, 126, 110062.	2.5	11
738	Impaired Anti-Tumor T cell Response in Hepatocellular Carcinoma. <i>Cancers</i> , 2020, 12, 627.	1.7	22
739	Obesity and CD8 T cell metabolism: Implications for anti-tumor immunity and cancer immunotherapy outcomes. <i>Immunological Reviews</i> , 2020, 295, 203-219.	2.8	25
740	Myeloid derived suppressor cells are reduced and T regulatory cells stabilised in patients with advanced pancreatic cancer treated with gemcitabine and intravenous omega 3. <i>Annals of Translational Medicine</i> , 2020, 8, 172-172.	0.7	8
741	Tumor Microenvironment. <i>Cancer Treatment and Research</i> , 2020, , .	0.2	12
742	Blood Myeloid-Derived Suppressor Cells Correlate with Neutrophil-to-Lymphocyte Ratio and Overall Survival in Metastatic Urothelial Carcinoma. <i>Targeted Oncology</i> , 2020, 15, 211-220.	1.7	14
743	Myeloid-Derived Suppressor Cells as a Therapeutic Target for Cancer. <i>Cells</i> , 2020, 9, 561.	1.8	281
744	The DNA methyltransferase inhibitor, guadecitabine, targets tumor-induced myelopoiesis and recovers T cell activity to slow tumor growth in combination with adoptive immunotherapy in a mouse model of breast cancer. <i>BMC Immunology</i> , 2020, 21, 8.	0.9	19
745	Anticancer Effects of ACT001 via NF- κ B Suppression in Murine Triple-Negative Breast Cancer Cell Line 4T1. <i>Cancer Management and Research</i> , 2020, Volume 12, 5131-5139.	0.9	15
746	Interleukin-1 β and Cancer. <i>Cancers</i> , 2020, 12, 1791.	1.7	146

#	ARTICLE	IF	CITATIONS
747	Renal cancer-derived exosomes induce tumor immune tolerance by MDSCs-mediated antigen-specific immunosuppression. <i>Cell Communication and Signaling</i> , 2020, 18, 106.	2.7	29
749	Defining the emergence of myeloid-derived suppressor cells in breast cancer using single-cell transcriptomics. <i>Science Immunology</i> , 2020, 5, .	5.6	296
750	Nano-puerarin regulates tumor microenvironment and facilitates chemo- and immunotherapy in murine triple negative breast cancer model. <i>Biomaterials</i> , 2020, 235, 119769.	5.7	93
751	Functional assay to assess T-cell inhibitory properties of myeloid derived suppressor cells (MDSCs) isolated from the tumor microenvironment of murine glioma models. <i>Methods in Enzymology</i> , 2020, 632, 215-228.	0.4	5
752	Ibrutinib treatment inhibits breast cancer progression and metastasis by inducing conversion of myeloid-derived suppressor cells to dendritic cells. <i>British Journal of Cancer</i> , 2020, 122, 1005-1013.	2.9	52
753	Underlying Ossification Phenotype in a Murine Model of Metastatic Synovial Sarcoma. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2636.	1.8	2
754	Contribution of Macrophages and T Cells in Skeletal Metastasis. <i>Cancers</i> , 2020, 12, 1014.	1.7	19
755	Myeloid-Derived Suppressor Cell Subsets Drive Glioblastoma Growth in a Sex-Specific Manner. <i>Cancer Discovery</i> , 2020, 10, 1210-1225.	7.7	138
756	Microenvironmental Determinants of Pancreatic Cancer. <i>Physiological Reviews</i> , 2020, 100, 1707-1751.	13.1	156
757	Immune suppression in gliomas. <i>Journal of Neuro-Oncology</i> , 2021, 151, 3-12.	1.4	167
758	Myeloid-derived suppressor cells and regulatory T cells share common immunoregulatory pathways-related microRNAs that are dysregulated by acute lymphoblastic leukemia and chemotherapy. <i>Human Immunology</i> , 2021, 82, 36-45.	1.2	8
759	Implications of metabolism-driven myeloid dysfunctions in cancer therapy. <i>Cellular and Molecular Immunology</i> , 2021, 18, 829-841.	4.8	21
760	Role of Myeloid-Derived Suppressor Cells in High-Dose-Irradiated TRAMP-C1 Tumors: A Therapeutic Target and an Index for Assessing Tumor Microenvironment. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 1547-1558.	0.4	10
761	Targeted Deletion of CXCR2 in Myeloid Cells Alters the Tumor Immune Environment to Improve Antitumor Immunity. <i>Cancer Immunology Research</i> , 2021, 9, 200-213.	1.6	42
762	Myeloid-Derived Suppressor Cells. <i>Methods in Molecular Biology</i> , 2021, , .	0.4	2
763	Polymorphonuclear-MDSCs Facilitate Tumor Regrowth After Radiation by Suppressing CD8+ T Cells. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 1533-1546.	0.4	19
764	Anti-pulmonary metastases from cervical cancer responses induced by a human papillomavirus peptide vaccine adjuvanted with CpG-oligodeoxynucleotides in vivo. <i>International Immunopharmacology</i> , 2021, 90, 107203.	1.7	3
765	Reactive oxygen species in immune cells: A new antitumor target. <i>Biomedicine and Pharmacotherapy</i> , 2021, 133, 110978.	2.5	34

#	ARTICLE	IF	CITATIONS
766	Recent advances in myeloid-derived suppressor cell biology. <i>Frontiers of Medicine</i> , 2021, 15, 232-251.	1.5	17
767	The tumour immune landscape and its implications in cutaneous melanoma. <i>Pigment Cell and Melanoma Research</i> , 2021, 34, 529-549.	1.5	21
768	The balance between breast cancer and the immune system: Challenges for prognosis and clinical benefit from immunotherapies. <i>Seminars in Cancer Biology</i> , 2021, 72, 76-89.	4.3	87
769	Non-depleting reformation of immunosuppressive myeloid cells to broaden the application of anti-PD therapy. <i>Nanoscale</i> , 2021, 13, 4420-4431.	2.8	13
770	Immunosuppressive effects and mechanisms of three myeloid-derived suppressor cells subsets including monocytic-myeloid-derived suppressor cells, granulocytic-myeloid-derived suppressor cells, and immature-myeloid-derived suppressor cells. <i>Journal of Cancer Research and Therapeutics</i> , 2021, 17, 1093.	0.3	5
771	The Monocytes That Repopulate in Mice After Cyclophosphamide Treatment Acquire a Neutrophil Precursor Gene Signature and Immunosuppressive Activity. <i>Frontiers in Immunology</i> , 2020, 11, 594540.	2.2	6
772	Targeting myeloid-derived suppressor cells for cancer therapy. <i>Cancer Biology and Medicine</i> , 2021, 18, 0-0.	1.4	12
773	Nod1 promotes colorectal carcinogenesis by regulating the immunosuppressive functions of tumor-infiltrating myeloid cells. <i>Cell Reports</i> , 2021, 34, 108677.	2.9	44
774	Auswirkungen von Chemotherapeutika auf zirkulierende Leukozytenpopulationen: Mögliche Implikationen für den Erfolg von CAR-T-Zell-Therapien. <i>Karger Kompass Onkologie</i> , 2021, 8, 116-127.	0.0	0
775	Immune System Efficiency in Cancer and the Microbiota Influence. <i>Pathobiology</i> , 2021, 88, 170-186.	1.9	14
776	The Functional Crosstalk between Myeloid-Derived Suppressor Cells and Regulatory T Cells within the Immunosuppressive Tumor Microenvironment. <i>Cancers</i> , 2021, 13, 210.	1.7	86
777	Recent Discoveries of Macromolecule- and Cell-Based Biomarkers and Therapeutic Implications in Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2021, 22, 636.	1.8	29
778	Role of myeloid-derived suppressor cells in metastasis. <i>Cancer and Metastasis Reviews</i> , 2021, 40, 391-411.	2.7	22
779	Other cells of the tumor microenvironment. , 2021, , 113-138.		0
780	Immune-modulating Effect of Korean Red Ginseng by Balancing the Ratio of Peripheral T Lymphocytes in Bile Duct or Pancreatic Cancer Patients With Adjuvant Chemotherapy. <i>In Vivo</i> , 2021, 35, 1895-1900.	0.6	6
781	IL-15/IL-15R α Heterodimeric Complex as Cancer Immunotherapy in Murine Breast Cancer Models. <i>Frontiers in Immunology</i> , 2020, 11, 614667.	2.2	9
782	Immunotherapy for pancreatic ductal adenocarcinoma. <i>Journal of Surgical Oncology</i> , 2021, 123, 751-759.	0.8	18
783	Control of Gene Expression by Exosome-Derived Non-Coding RNAs in Cancer Angiogenesis and Lymphangiogenesis. <i>Biomolecules</i> , 2021, 11, 249.	1.8	15

#	ARTICLE	IF	CITATIONS
784	Reactive myelopoiesis and the onset of myeloid-mediated immune suppression: Implications for adoptive cell therapy. <i>Cellular Immunology</i> , 2021, 361, 104277.	1.4	4
785	The Peripheral Immune Landscape of Breast Cancer: Clinical Findings and In Vitro Models for Biomarker Discovery. <i>Cancers</i> , 2021, 13, 1305.	1.7	14
786	The Relationship between Hepatic Myeloid-Derived Suppressor Cells and Clinicopathological Parameters in Patients with Chronic Liver Disease. <i>BioMed Research International</i> , 2021, 2021, 1-10.	0.9	6
787	The role of tumor heterogeneity in immune-tumor interactions. <i>Cancer and Metastasis Reviews</i> , 2021, 40, 377-389.	2.7	12
788	Immune suppressive activity of myeloid-derived suppressor cells in cancer requires inactivation of the type I interferon pathway. <i>Nature Communications</i> , 2021, 12, 1717.	5.8	53
789	Melatonin decreases metastasis, primary tumor growth and angiogenesis in a mice model of breast cancer. <i>Human and Experimental Toxicology</i> , 2021, 40, 1545-1557.	1.1	11
790	Radiotherapy and cGAS/STING signaling: Impact on MDSCs in the tumor microenvironment. <i>Cellular Immunology</i> , 2021, 362, 104298.	1.4	35
791	Novel combinatorial strategies for boosting the efficacy of immune checkpoint inhibitors in advanced breast cancers. <i>Clinical and Translational Oncology</i> , 2021, 23, 1979-1994.	1.2	18
792	Granulocytes and Cells of Granulocyte Originâ€”The Relevant Players in Colorectal Cancer. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3801.	1.8	6
793	MDSCs, ageing and inflammaging. <i>Cellular Immunology</i> , 2021, 362, 104297.	1.4	30
794	Myelopoiesis during Solid Cancers and Strategies for Immunotherapy. <i>Cells</i> , 2021, 10, 968.	1.8	7
795	Resistance to Immune Checkpoint Inhibitors Secondary to Myeloid-Derived Suppressor Cells: A New Therapeutic Targeting of Haematological Malignancies. <i>Journal of Clinical Medicine</i> , 2021, 10, 1919.	1.0	5
796	Effects of Chemotherapy Agents on Circulating Leukocyte Populations: Potential Implications for the Success of CAR-T Cell Therapies. <i>Cancers</i> , 2021, 13, 2225.	1.7	21
797	Liver Immune Microenvironment and Metastasis from Colorectal Cancer-Pathogenesis and Therapeutic Perspectives. <i>Cancers</i> , 2021, 13, 2418.	1.7	36
798	Inhibition of CCL7 derived from Mo-MDSCs prevents metastatic progression from latency in colorectal cancer. <i>Cell Death and Disease</i> , 2021, 12, 484.	2.7	20
799	Human splenic myeloid derived suppressor cells: Phenotypic and clustering analysis. <i>Cellular Immunology</i> , 2021, 363, 104317.	1.4	13
800	Breast cancer dormancy: need for clinically relevant models to address current gaps in knowledge. <i>Npj Breast Cancer</i> , 2021, 7, 66.	2.3	35
801	Natural Killer Cell Interactions With Myeloid Derived Suppressor Cells in the Tumor Microenvironment and Implications for Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 2021, 12, 633205.	2.2	42

#	ARTICLE	IF	CITATIONS
802	Coordinated regulation of immune contexture: crosstalk between STAT3 and immune cells during breast cancer progression. <i>Cell Communication and Signaling</i> , 2021, 19, 50.	2.7	14
803	Delineating the breast cancer immune microenvironment in the era of multiplex immunohistochemistry/immunofluorescence. <i>Histopathology</i> , 2021, 79, 139-159.	1.6	9
804	Myeloid derived suppressor cells and the release of micro-metastases from dormancy. <i>Clinical and Experimental Metastasis</i> , 2021, 38, 279-293.	1.7	6
805	Hypoxia and its impact on the tumour microenvironment of gastroesophageal cancers. <i>World Journal of Gastrointestinal Oncology</i> , 2021, 13, 312-331.	0.8	7
806	Regulatory Effects of Histone Deacetylase Inhibitors on Myeloid-Derived Suppressor Cells. <i>Frontiers in Immunology</i> , 2021, 12, 690207.	2.2	13
807	Comments on the ambiguity of selected surface markers, signaling pathways and omics profiles hampering the identification of myeloid-derived suppressor cells. <i>Cellular Immunology</i> , 2021, 364, 104347.	1.4	4
808	Neutrophils in Tumorigenesis: Missing Targets for Successful Next Generation Cancer Therapies?. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6744.	1.8	15
809	Senescence and Aging: Does It Impact Cancer Immunotherapies?. <i>Cells</i> , 2021, 10, 1568.	1.8	12
810	Comparing the frequency of CD33 ⁺ pSTAT3 ⁺ myeloid-derived suppressor cells and IL17 ⁺ lymphocytes in patients with prostate cancer and benign prostatic hyperplasia. <i>Cell Biology International</i> , 2021, 45, 2086-2095.	1.4	5
811	Characteristics and Spatially Defined Immune (micro)landscapes of Early-stage PD-L1 ⁺ positive Triple-negative Breast Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 5628-5637.	3.2	32
812	Crosstalk between Tumor-Infiltrating Immune Cells and Cancer-Associated Fibroblasts in Tumor Growth and Immunosuppression of Breast Cancer. <i>Journal of Immunology Research</i> , 2021, 2021, 1-15.	0.9	15
813	Circulating immune biomarkers in peripheral blood correlate with clinical outcomes in advanced breast cancer. <i>Scientific Reports</i> , 2021, 11, 14426.	1.6	17
814	Myeloid-Derived Suppressor Cells: Implications in the Resistance of Malignant Tumors to T Cell-Based Immunotherapy. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 707198.	1.8	17
815	CD73 expression in myeloid-derived suppressor cells is correlated with clinical stages in head and neck squamous cell carcinomas. <i>Annals of Translational Medicine</i> , 2021, 9, 1148-1148.	0.7	8
816	Stem cells-derived natural killer cells for cancer immunotherapy: current protocols, feasibility, and benefits of ex vivo generated natural killer cells in treatment of advanced solid tumors. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 3369-3395.	2.0	3
817	Orchestration of myeloid-derived suppressor cells in the tumor microenvironment by ubiquitous cellular protein TCTP released by tumor cells. <i>Nature Immunology</i> , 2021, 22, 947-957.	7.0	37
818	Regulation of the epigenetic landscape by immune cell oxidants. <i>Free Radical Biology and Medicine</i> , 2021, 170, 131-149.	1.3	8
819	Immune checkpoint blockade in triple negative breast cancer influenced by B cells through myeloid-derived suppressor cells. <i>Communications Biology</i> , 2021, 4, 859.	2.0	13

#	ARTICLE	IF	CITATIONS
820	Heterogeneous Myeloid Cells in Tumors. <i>Cancers</i> , 2021, 13, 3772.	1.7	30
821	Multimodal Intralesional Therapy for Reshaping the Myeloid Compartment of Tumors Resistant to Anti-PD-L1 Therapy via IRF8 Expression. <i>Journal of Immunology</i> , 2021, 207, 1298-1309.	0.4	8
822	Analysis of the circulating myeloid-derived suppressor cells during androgen deprivation therapy for prostate cancer. <i>IJU Case Reports</i> , 2021, 4, 367-370.	0.1	1
823	Small Extracellular Vesicles and Metastasis—Blame the Messenger. <i>Cancers</i> , 2021, 13, 4380.	1.7	11
825	Current Challenges in Targeting Tumor Desmoplasia to Improve the Efficacy of Immunotherapy. <i>Current Cancer Drug Targets</i> , 2021, 21, 919-931.	0.8	0
826	The impact of microRNAs on myeloid-derived suppressor cells in cancer. <i>Human Immunology</i> , 2021, 82, 668-678.	1.2	5
827	The Breast Tumor Microenvironment: A Key Player in Metastatic Spread. <i>Cancers</i> , 2021, 13, 4798.	1.7	26
828	Increased Blood Monocytic Myeloid Derived Suppressor Cells but Low Regulatory T Lymphocytes in Patients with Mild COVID-19. <i>Viral Immunology</i> , 2021, 34, 639-645.	0.6	13
829	Immunobiology of Melanoma. <i>Clinics in Plastic Surgery</i> , 2021, 48, 561-576.	0.7	5
830	Inhibition of NLRP3 inflammasome activation in myeloid-derived suppressor cells by andrographolide sulfonate contributes to 5-FU sensitization in mice. <i>Toxicology and Applied Pharmacology</i> , 2021, 428, 115672.	1.3	7
831	Cancer-associated fibroblasts induce monocytic myeloid-derived suppressor cell generation via IL-6/exosomal miR-21-activated STAT3 signaling to promote cisplatin resistance in esophageal squamous cell carcinoma. <i>Cancer Letters</i> , 2021, 518, 35-48.	3.2	76
832	Betulinic acid attenuates cyclophosphamide-induced intestinal mucosa injury by inhibiting the NF- κ B/MAPK signalling pathways and activating the Nrf2 signalling pathway. <i>Ecotoxicology and Environmental Safety</i> , 2021, 225, 112746.	2.9	22
833	Targeted delivery and reprogramming of myeloid-derived suppressor cells (MDSCs) in cancer. , 2022, , 409-435.		1
834	Myeloid-derived suppressor cells: Bridging the gap between inflammation and pancreatic adenocarcinoma. <i>Scandinavian Journal of Immunology</i> , 2021, 93, e13021.	1.3	6
835	Epithelial-to-mesenchymal Transition Heterogeneity of Circulating Tumor Cells and Their Correlation With MDSCs and Tregs in HER2-negative Metastatic Breast Cancer Patients. <i>Anticancer Research</i> , 2021, 41, 661-670.	0.5	11
836	Hematopoietic versus Solid Cancers and T Cell Dysfunction: Looking for Similarities and Distinctions. <i>Cancers</i> , 2021, 13, 284.	1.7	15
837	Myeloid-derived suppressor cells promote lung cancer metastasis by CCL11 to activate ERK and AKT signaling and induce epithelial-mesenchymal transition in tumor cells. <i>Oncogene</i> , 2021, 40, 1476-1489.	2.6	39
838	The Angiogenic Switch: Role of Immune Cells. , 2011, , 57-75.		2

#	ARTICLE	IF	CITATIONS
839	Escape Mechanisms from Antiangiogenic Therapy: An Immune Cell's Perspective. <i>Advances in Experimental Medicine and Biology</i> , 2014, 772, 83-99.	0.8	11
840	The Use of Dendritic Cells for Peptide-Based Vaccination in Cancer Immunotherapy. <i>Methods in Molecular Biology</i> , 2014, 1139, 479-503.	0.4	18
841	Myeloid-Derived Suppressor Cells in the Tumor Microenvironment. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1224, 117-140.	0.8	141
842	Fatty Acid Mediators in the Tumor Microenvironment. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1259, 125-153.	0.8	9
843	MIF-Dependent Regulation of Monocyte/Macrophage Polarization. , 2017, , 59-76.		1
844	The Role of Innate Immune Signaling in Regulation of Tumor-Associated Myeloid Cells. , 2015, , 25-47.		2
845	Effect of Chemotherapy on the Tumor Microenvironment and Anti-tumor Immunity. , 2013, , 1-28.		3
846	Increased levels of myeloid-derived suppressor cells in esophageal cancer patients is associated with the complication of sepsis. <i>Biomedicine and Pharmacotherapy</i> , 2020, 125, 109864.	2.5	10
849	Tumor-Induced Myeloid-Derived Suppressor Cells. , 0, , 833-856.		1
850	Neutralization of IL-8 decreases tumor PMN-MDSCs and reduces mesenchymalization of claudin-low triple-negative breast cancer. <i>JCI Insight</i> , 2017, 2, .	2.3	112
851	Therapies for tuberculosis and AIDS: myeloid-derived suppressor cells in focus. <i>Journal of Clinical Investigation</i> , 2020, 130, 2789-2799.	3.9	26
852	Myeloid-derived suppressor cells are implicated in regulating permissiveness for tumor metastasis during mouse gestation. <i>Journal of Clinical Investigation</i> , 2011, 121, 2794-2807.	3.9	86
853	STAT3 regulates arginase-I in myeloid-derived suppressor cells from cancer patients. <i>Journal of Clinical Investigation</i> , 2013, 123, 1580-1589.	3.9	430
854	Myeloid-derived suppressor cell development is regulated by a STAT/IRF-8 axis. <i>Journal of Clinical Investigation</i> , 2013, 123, 4464-4478.	3.9	261
855	Vaccine-induced myeloid cell population dampens protective immunity to SIV. <i>Journal of Clinical Investigation</i> , 2014, 124, 2538-2549.	3.9	58
856	Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected. <i>Journal of Clinical Investigation</i> , 2015, 125, 3356-3364.	3.9	846
857	Tumor-induced myeloid deviation: when myeloid-derived suppressor cells meet tumor-associated macrophages. <i>Journal of Clinical Investigation</i> , 2015, 125, 3365-3376.	3.9	443
858	Increased Circulating Myeloid-Derived Suppressor Cells and S100A8 Correlate with Clinical Stage in Nasopharyngeal Carcinoma. <i>International Journal of Otorhinolaryngology</i> , 2015, 2, .	1.0	1

#	ARTICLE	IF	CITATIONS
859	Characterization of the MDSC Proteome Associated with Metastatic Murine Mammary Tumors Using Label-Free Mass Spectrometry and Shotgun Proteomics. <i>PLoS ONE</i> , 2011, 6, e22446.	1.1	35
860	Excess Circulating Alternatively Activated Myeloid (M2) Cells Accelerate ALS Progression While Inhibiting Experimental Autoimmune Encephalomyelitis. <i>PLoS ONE</i> , 2011, 6, e26921.	1.1	54
861	Peripheral Immune Cell Gene Expression Predicts Survival of Patients with Non-Small Cell Lung Cancer. <i>PLoS ONE</i> , 2012, 7, e34392.	1.1	23
862	Pancreatic Tumors and Immature Immunosuppressive Myeloid Cells in Blood and Spleen: Role of Inhibitory Co-Stimulatory Molecules PDL1 and CTLA4. An In Vivo and In Vitro Study. <i>PLoS ONE</i> , 2013, 8, e54824.	1.1	44
863	The Peripheral Myeloid Expansion Driven by Murine Cancer Progression Is Reversed by Radiation Therapy of the Tumor. <i>PLoS ONE</i> , 2013, 8, e69527.	1.1	36
864	Immune Monitoring of the Circulation and the Tumor Microenvironment in Patients with Regionally Advanced Melanoma Receiving Neoadjuvant Ipilimumab. <i>PLoS ONE</i> , 2014, 9, e87705.	1.1	261
865	MDSCs Mediate Angiogenesis and Predispose Canine Mammary Tumor Cells for Metastasis via IL-28/IL-28RA (IFN- λ) Signaling. <i>PLoS ONE</i> , 2014, 9, e103249.	1.1	47
866	TGF β ² Signaling in Myeloid Cells Regulates Mammary Carcinoma Cell Invasion through Fibroblast Interactions. <i>PLoS ONE</i> , 2015, 10, e0117908.	1.1	17
867	Pre-Vaccination Frequencies of Th17 Cells Correlate with Vaccine-Induced T-Cell Responses to Survivin-Derived Peptide Epitopes. <i>PLoS ONE</i> , 2015, 10, e0131934.	1.1	11
868	Neutrophil-to-Lymphocyte Ratio Predicts PSA Response and Prognosis in Prostate Cancer: A Systematic Review and Meta-Analysis. <i>PLoS ONE</i> , 2016, 11, e0158770.	1.1	47
869	Paradoxical myeloid-derived suppressor cell reduction in the bone marrow of SIV chronically infected macaques. <i>PLoS Pathogens</i> , 2017, 13, e1006395.	2.1	24
870	Myelopoiesis, metabolism and therapy: a crucial crossroads in cancer progression. <i>Cell Stress</i> , 2019, 3, 284-294.	1.4	40
872	Knockout of MDA-9/Syntenin (SDCBP) expression in the microenvironment dampens tumor-supporting inflammation and inhibits melanoma metastasis. <i>Oncotarget</i> , 2016, 7, 46848-46861.	0.8	28
873	Accumulation of myeloid-derived suppressor cells (MDSCs) induced by low levels of IL-6 correlates with poor prognosis in bladder cancer. <i>Oncotarget</i> , 2017, 8, 38378-38388.	0.8	83
874	The peripheral immune status of granulocytic myeloid-derived suppressor cells correlates the survival in advanced gastric cancer patients receiving cisplatin-based chemotherapy. <i>Oncotarget</i> , 2017, 8, 95083-95094.	0.8	15
875	Activation of VIP signaling enhances immunosuppressive effect of MDSCs on CMV-induced adaptive immunity. <i>Oncotarget</i> , 2017, 8, 81873-81879.	0.8	9
876	CXCR2+ MDSCs promote breast cancer progression by inducing EMT and activated T cell exhaustion. <i>Oncotarget</i> , 2017, 8, 114554-114567.	0.8	86
877	Estrogen stimulates female cancer progression by inducing myeloid-derived suppressive cells: investigations on pregnant and non-pregnant experimental models. <i>Oncotarget</i> , 2019, 10, 1887-1902.	0.8	21

#	ARTICLE	IF	CITATIONS
878	Cysteine cathepsin activity suppresses osteoclastogenesis of myeloid-derived suppressor cells in breast cancer. <i>Oncotarget</i> , 2015, 6, 27008-27022.	0.8	39
879	Taxanes enhance trastuzumab-mediated ADCC on tumor cells through NKG2D-mediated NK cell recognition. <i>Oncotarget</i> , 2016, 7, 255-265.	0.8	39
880	Bevacizumab specifically decreases elevated levels of circulating KIT+CD11b+ cells and IL-10 in metastatic breast cancer patients. <i>Oncotarget</i> , 2016, 7, 11137-11150.	0.8	14
881	Signal transducer and activator of transcription 3 in myeloid-derived suppressor cells: an opportunity for cancer therapy. <i>Oncotarget</i> , 0, 7, 42698-42715.	0.8	34
882	Clinical implications of neutrophil-to-lymphocyte ratio and MDSC kinetics in gastric cancer patients treated with ramucirumab plus paclitaxel. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association</i> , Beijing Institute for Cancer Research, 2020, 32, 621-630.	0.7	7
883	Myeloid-Derived Suppressor Cells in Some Oncohematological Diseases. <i>Klinicheskaya Onkogematologiya/Clinical Oncohematology</i> , 2017, 10, 29-38.	0.1	2
884	Inflammation Fuels Tumor Progress and Metastasis. <i>Current Pharmaceutical Design</i> , 2015, 21, 3032-3040.	0.9	69
885	Role of Nuclear Factor Erythroid 2-Related Factor 2 (NRF-2) Mediated Antioxidant Response on the Synergistic Antitumor Effect of L-Arginine and 5-Fluoro Uracil (5FU) in Breast Adenocarcinoma. <i>Current Pharmaceutical Design</i> , 2019, 25, 1643-1652.	0.9	8
886	Increased frequency and clinical significance of myeloid-derived suppressor cells in human colorectal carcinoma. <i>World Journal of Gastroenterology</i> , 2012, 18, 3303-9.	1.4	117
887	MicroRNAs: Novel immunotherapeutic targets in colorectal carcinoma. <i>World Journal of Gastroenterology</i> , 2016, 22, 5317.	1.4	48
888	The role of granulocyte colony-stimulating factor in breast cancer development: A review. <i>Molecular Medicine Reports</i> , 2020, 21, 2019-2029.	1.1	19
889	Combination of preoperative fibrinogen concentration and neutrophil-to-lymphocyte ratio for prediction of the prognosis of patients with resectable breast cancer. <i>Oncology Letters</i> , 2020, 20, 1-1.	0.8	6
890	Dual roles of myeloid-derived suppressor cells induced by Toll-like receptor signaling in cancer (Review). <i>Oncology Letters</i> , 2020, 21, 149.	0.8	16
891	Serum Soluble Interleukin-2 Receptor is Increased in Malnourished and Immunosuppressed Patients With Gastric and Colorectal Cancer: Possible Influence of Myeloid-Derived Suppressor Cells. <i>World Journal of Oncology</i> , 2012, 3, 158-164.	0.6	7
892	Myxomaviral Anti-Inflammatory Serpin Reduces Myeloid-Derived Suppressor Cells and Human Pancreatic Cancer Cell Growth in Mice. <i>Journal of Cancer Science & Therapy</i> , 2013, 05, 291-299.	1.7	13
893	Myeloid-derived suppressor cells and associated events in urethane-induced lung cancer. <i>Clinics</i> , 2013, 68, 858-864.	0.6	4
894	Postoperative Natural Killer Cell Dysfunction: The Prime Suspect in the Case of Metastasis Following Curative Cancer Surgery. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11378.	1.8	13
895	Therapeutic resistance in pancreatic ductal adenocarcinoma: Current challenges and future opportunities. <i>World Journal of Gastroenterology</i> , 2021, 27, 6527-6550.	1.4	23

#	ARTICLE	IF	CITATIONS
897	Myeloid-Derived Suppressor Cells in Cancer. , 2012, , 217-229.		0
899	Tumor Inflammatory Microenvironment in EMT and Metastasis. , 0, , .		1
900	Cell Lineage Commitment and Tumor Microenvironment as Determinants for Tumor-Associated Myelomonocytic Cells Plasticity. , 0, , .		0
901	Inflammation, Tumor Progression, and Immune Suppression. , 2013, , 177-196.		0
902	Approaches to Immunologic Monitoring of Clinical Trials. , 2013, , 663-694.		0
903	Day 100 Absolute Monocyte/Lymphocyte Prognostic Score and Survival Post Autologous Peripheral Blood Hematopoietic Stem Cell Transplantation in Diffuse Large B-Cell Lymphoma. Journal of Cancer Therapy, 2013, 04, 1298-1305.	0.1	0
904	Analysis of Myeloid-Derived Suppressor Cells in Patients with Cancer. , 2013, , 707-723.		0
905	Innate and Adaptive Immune Responses to Cancer. , 2014, , 81-121.		1
906	Myeloid-Derived Suppressor Cells in Cancer. , 2014, , 3-17.		0
907	Myeloid-Derived Suppressor Cells and Tumor Growth. , 2014, , 91-109.		2
908	Low-Dose Chemomodulation and Cancer Vaccines. Journal of Vaccines & Vaccination, 2014, 05, .	0.3	0
909	Myeloid-Derived Suppressor Cells in Tumor-Induced T Cell Suppression and Tolerance. , 2014, , 99-150.		2
910	Non-small Cell Lung Cancer, NSCLC. , 2014, , 193-201.		2
911	Frontiers in Cancer Immunotherapy. , 2015, , 1-22.		1
912	Myeloid derived suppressor cells in breast cancer: A novel therapeutic target?. World Journal of Immunology, 2015, 6, 119.	0.5	0
914	Signal Transducer and Activation of Transcription 3: A Master Regulator of Myeloid-Derived Suppressor Cells. SpringerBriefs in Immunology, 2016, , 73-90.	0.1	0
915	Controversies in Neoplastic Myeloplasia. SpringerBriefs in Immunology, 2016, , 1-24.	0.1	0
916	IL-17 and VEGF are significantly associated with disease progression involving systemic inflammation in patients with gastric and colorectal cancers. Annals of Cancer Research and Therapy, 2017, 25, 67-76.	0.1	5

#	ARTICLE	IF	CITATIONS
917	Cytokine-Induced Killer Cells for the Adjuvant Treatment of Patients with HCC. , 2017, , 69-84.		0
918	Immunotherapy and Targeted Therapies in Advanced Castration Resistant Prostate Cancer. , 2017, , 357-377.		1
919	Tumor-Promoting/Associated Inflammation and the Microenvironment: A State of the Science and New Horizons. , 0, , 473-510.		0
920	Innate and Adaptive Immune Responses to Cancer. , 2019, , 111-159.		3
921	IL-17A in oncology. Annals of Cancer Research and Therapy, 2019, 27, 59-63.	0.1	2
923	Immunopathology as a Basis for Immunotherapy of Head and Neck Squamous Cell Carcinoma. , 2020, , 333-354.		0
924	Natural Killer Cells Expanded and Preactivated Exhibit Enhanced Antitumor Activity against Different Tumor Cells in Vitro. Asian Pacific Journal of Cancer Prevention, 2020, 21, 1595-1605.	0.5	2
925	Metronomic Anti-Cancer Therapy: A Multimodal Therapy Governed by the Tumor Microenvironment. Cancers, 2021, 13, 5414.	1.7	8
926	Pembrolizumab Plus Gemcitabine in the Subset of Triple-Negative Advanced Breast Cancer Patients in the GEICAM/2015-04 (PANGEA-Breast) Study. Cancers, 2021, 13, 5432.	1.7	4
927	Correlation analysis of the proportion of monocytic myeloid-derived suppressor cells in colorectal cancer patients. PLoS ONE, 2020, 15, e0243643.	1.1	6
928	Cyclooxygenase-2 contributes to mutant epidermal growth factor receptor lung tumorigenesis by promoting an immunosuppressive environment. Cancer Translational Medicine, 2020, 6, 40.	0.2	0
929	The Immune Landscape in Women Cancers. Cancer Treatment and Research, 2020, 180, 215-249.	0.2	3
930	Evaluation of immunomodulatory effects of lomefloxacin in mice. Brazilian Journal of Pharmaceutical Sciences, 0, 56, .	1.2	2
931	IL-17A in Ovarian Cancer. Journal of Cancer Therapy, 2020, 11, 605-616.	0.1	1
933	Response to FEC Chemotherapy and Oncolytic HSV-1 Is Associated with Macrophage Polarization and Increased Expression of S100A8/A9 in Triple Negative Breast Cancer. Cancers, 2021, 13, 5590.	1.7	0
934	Frontiers in Cancer Immunotherapy. , 2021, , 1-23.		0
935	IL-17A in Ovarian Cancer. Journal of Cancer Therapy, 2020, 11, 605-616.	0.1	0
936	The importance of advanced cytometry in defining new immune cell types and functions relevant for the immunopathogenesis of HIV infection. Aids, 2020, 34, 2169-2185.	1.0	2

#	ARTICLE	IF	CITATIONS
937	In Vitro Generation of Human Neutrophilic Myeloid-Derived Suppressor Cells. <i>Methods in Molecular Biology</i> , 2021, 2236, 77-83.	0.4	4
939	Detection of immune suppressive neutrophils in peripheral blood samples of cancer patients. <i>American Journal of Blood Research</i> , 2013, 3, 239-45.	0.6	27
940	Role of inflammation and inflammatory mediators in colorectal cancer. <i>Transactions of the American Clinical and Climatological Association</i> , 2014, 125, 358-72; discussion 372-3.	0.9	37
941	Increased circulating myeloid-derived suppressor cells correlate with cancer stages, interleukin-8 and -6 in prostate cancer. <i>International Journal of Clinical and Experimental Medicine</i> , 2014, 7, 3181-92.	1.3	50
942	The diverse roles of the TNF axis in cancer progression and metastasis. <i>Trends in Cancer Research</i> , 2016, 11, 1-27.	1.6	77
945	TGF- β 2 Enhances the Anti-inflammatory Effect of Tumor- Infiltrating CD33+11b+HLA-DR Myeloid-Derived Suppressor Cells in Gastric Cancer: A Possible Relation to MicroRNA-494. <i>Asian Pacific Journal of Cancer Prevention</i> , 2020, 21, 3393-3403.	0.5	3
946	The role of myeloid-derived suppressor cells in lung cancer and targeted immunotherapies. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 65-81.	1.1	9
947	Selectively targeting myeloid-derived suppressor cells through TRAIL receptor 2 to enhance the efficacy of CAR T cell therapy for treatment of breast cancer. , 2021, 9, e003237.		29
948	The effect of leg ischemia/reperfusion injury on the liver in an experimental breast cancer model. <i>Journal of Surgery and Medicine</i> , 2021, 5, 1079-1085.	0.0	0
949	Fc γ RIIB potentiates differentiation of myeloid-derived suppressor cells to mediate tumor immunoescape. <i>Theranostics</i> , 2022, 12, 842-858.	4.6	5
950	TGF- β 2 Enhances the Anti-inflammatory Effect of Tumor- Infiltrating CD33+11b+HLA-DR Myeloid-Derived Suppressor Cells in Gastric Cancer: A Possible Relation to MicroRNA-494. <i>Asian Pacific Journal of Cancer Prevention</i> , 2020, 21, 3393-3403.	0.5	7
951	Myeloid Diagnostic and Prognostic Markers of Immune Suppression in the Blood of Glioma Patients. <i>Frontiers in Immunology</i> , 2021, 12, 809826.	2.2	8
952	Inflammation and Myeloid Cells in Cancer Progression and Metastasis. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 759691.	1.8	12
953	Myeloid-Derived Suppressor Cells in Solid Tumors. <i>Cells</i> , 2022, 11, 310.	1.8	39
954	Extracellular Vesicles as Mediators of Therapy Resistance in the Breast Cancer Microenvironment. <i>Biomolecules</i> , 2022, 12, 132.	1.8	7
955	Immunometabolism in biofilm infection: lessons from cancer. <i>Molecular Medicine</i> , 2022, 28, 10.	1.9	18
956	Early Recovery of Myeloid-Derived Suppressor Cells After Allogeneic Hematopoietic Transplant: Comparison of Post-Transplantation Cyclophosphamide to Standard Graft-Versus-Host Disease Prophylaxis. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 203.e1-203.e7.	0.6	7
957	Targeting myeloid-derived suppressor cells to enhance natural killer cell-based immunotherapy. , 2022, 235, 108114.		13

#	ARTICLE	IF	CITATIONS
958	New Discovery of Myeloid-Derived Suppressor Cellâ€™s Tale on Viral Infection and COVID-19. <i>Frontiers in Immunology</i> , 2022, 13, 842535.	2.2	7
959	Mo-MDSCs are pivotal players in colorectal cancer and may be associated with tumor recurrence after surgery. <i>Translational Oncology</i> , 2022, 17, 101346.	1.7	6
960	Tumor Microenvironment in Pancreatic Intraepithelial Neoplasia. <i>Cancers</i> , 2021, 13, 6188.	1.7	12
961	Emerging mechanisms of immunotherapy resistance in sarcomas. <i>Cancer Drug Resistance (Alhambra,)</i> Tj ETQq1 1 0,784314 rgBT /Ov	0.9	1
962	The Role of Myeloid-Derived Suppressor Cells in Tumor Growth and Metastasis. <i>Experientia Supplementum (2012)</i> , 2022, 113, 189-217.	0.5	6
963	Deciphering mechanisms of immune escape to inform immunotherapeutic strategies in multiple myeloma. <i>Journal of Hematology and Oncology</i> , 2022, 15, 17.	6.9	46
964	Immunometabolism of Myeloid-Derived Suppressor Cells: Implications for Mycobacterium tuberculosis Infection and Insights from Tumor Biology. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3512.	1.8	3
965	Exploration of Novel Pathways Underlying Irreversible Electroporation Induced Anti-Tumor Immunity in Pancreatic Cancer. <i>Frontiers in Oncology</i> , 2022, 12, 853779.	1.3	6
966	Cytarabineâ€ induced TNFÎ± promotes the expansion and suppressive functions of myeloidâ€ derived suppressor cells in acute myeloid leukaemia. <i>Scandinavian Journal of Immunology</i> , 2022, 95, e13158.	1.3	3
967	Splenic and PB immune recovery in neoadjuvant treated gastrointestinal cancer patients. <i>International Immunopharmacology</i> , 2022, 106, 108628.	1.7	1
968	Targeting Myeloid-Derived Suppressor Cells Derived From Surgical Stress: The Key to Prevent Post-surgical Metastasis. <i>Frontiers in Surgery</i> , 2021, 8, 783218.	0.6	4
969	Nitrogen-Doped Carbon Nanotube Cups for Cancer Therapy. <i>ACS Applied Nano Materials</i> , 2022, 5, 13685-13696.	2.4	4
970	Impact of Immune Cell Heterogeneity on HER2+ Breast Cancer Prognosis and Response to Therapy. <i>Cancers</i> , 2021, 13, 6352.	1.7	2
971	Myeloid-Derived Suppressor Cells in Prostate Cancer: Present Knowledge and Future Perspectives. <i>Cells</i> , 2022, 11, 20.	1.8	17
972	Identification of a combined apoptosis and hypoxia gene signature for predicting prognosis and immune infiltration in breast cancer. <i>Cancer Medicine</i> , 2022, 11, 3886-3901.	1.3	9
973	High Levels of Circulating Monocytic Myeloid-Derived Suppressive-Like Cells Are Associated With the Primary Resistance to Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer: An Exploratory Analysis. <i>Frontiers in Immunology</i> , 2022, 13, 866561.	2.2	15
997	The Cellular Tumor Immune Microenvironment of Childhood Solid Cancers: Informing More Effective Immunotherapies. <i>Cancers</i> , 2022, 14, 2177.	1.7	2
998	Immune effects of CDK4/6 inhibitors in patients with HR+/HER2â€™ metastatic breast cancer: Relief from immunosuppression is associated with clinical response. <i>EBioMedicine</i> , 2022, 79, 104010.	2.7	22

#	ARTICLE	IF	CITATIONS
999	Activation of Host-NLRP3 Inflammasome in Myeloid Cells Dictates Response to Anti-PD-1 Therapy in Metastatic Breast Cancers. <i>Pharmaceuticals</i> , 2022, 15, 574.	1.7	9
1000	Neutrophils and polymorphonuclear myeloid-derived suppressor cells: an emerging battleground in cancer therapy. <i>Oncogenesis</i> , 2022, 11, 22.	2.1	16
1001	The breast cancer immune microenvironment is modified by neoadjuvant chemotherapy. <i>Scientific Reports</i> , 2022, 12, 7981.	1.6	15
1002	Using Single Cell Transcriptomics to Elucidate the Myeloid Compartment in Pancreatic Cancer. <i>Frontiers in Oncology</i> , 2022, 12, .	1.3	3
1003	Targeted regulation of tumor microenvironment through the inhibition of MDSCs by curcumin loaded self-assembled nano-filaments. <i>Materials Today Bio</i> , 2022, 15, 100304.	2.6	8
1004	Upregulation of Atypical Cadherin FAT1 Promotes an Immunosuppressive Tumor Microenvironment via TGF- β 2. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	11
1005	Myeloid-Derived Suppressor Cells May Predict the Occurrence of Postoperative Complications in Colorectal Cancer Patientsâ€™a Pilot Study. <i>Journal of Gastrointestinal Surgery</i> , 2022, 26, 2354-2357.	0.9	0
1006	Myeloid-derived suppressor cells cross-talk with B10 cells by BAFF/BAFF-R pathway to promote immunosuppression in cervical cancer. <i>Cancer Immunology, Immunotherapy</i> , 2023, 72, 73-85.	2.0	6
1007	Regional infusion of a class C TLR9 agonist enhances liver tumor microenvironment reprogramming and MDSC reduction to improve responsiveness to systemic checkpoint inhibition. <i>Cancer Gene Therapy</i> , 2022, 29, 1854-1865.	2.2	4
1008	Beneficial Modulatory Effects of Treatment With Bone Marrow Lysate on Hematopoietic Stem Cells and Myeloid Cells in Tumor-Bearing Mice. , 0, 79, .		0
1009	Innate immunity as a target for novel therapeutics in triple negative breast cancer. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 781-794.	1.9	2
1010	Immune-based therapies in penile cancer. <i>Nature Reviews Urology</i> , 2022, 19, 457-474.	1.9	14
1011	Dynamics of tumor-associated macrophages in a quantitative systems pharmacology model of immunotherapy in triple-negative breast cancer. <i>IScience</i> , 2022, 25, 104702.	1.9	15
1012	Myeloid-derived suppressor cells in cancer. , 2022, 1, 81-89.		1
1013	Myeloid-Derived Suppressor Cells and CD68+CD163+M2-Like Macrophages as Therapeutic Response Biomarkers Are Associated with Plasma Inflammatory Cytokines: A Preliminary Study for Non-Small Cell Lung Cancer Patients in Radiotherapy. <i>Journal of Immunology Research</i> , 2022, 2022, 1-16.	0.9	1
1014	Phototheranostics of Splenic Myeloid-Derived Suppressor Cells and Its Impact on Spleen Metabolism in Tumor-Bearing Mice. <i>Cancers</i> , 2022, 14, 3578.	1.7	5
1015	Treg-driven tumour control by PI3K $\hat{\gamma}$ inhibition limits myeloid-derived suppressor cell expansion. <i>British Journal of Cancer</i> , 2022, 127, 1595-1602.	2.9	5
1016	Replenishment of myeloid-derived suppressor cells (MDSCs) overrides CR-mediated protection against tumor growth in a murine model of triple-negative breast cancer. <i>GeroScience</i> , 2022, 44, 2471-2490.	2.1	2

#	ARTICLE	IF	CITATIONS
1017	Ethanol Ablation Therapy Drives Immune-Mediated Antitumor Effects in Murine Breast Cancer Models. <i>Cancers</i> , 2022, 14, 4669.	1.7	0
1018	Cancer prognosis and immune system. , 2022, , 75-144.		0
1019	The Urinary Microbiome: Role in Bladder Cancer and Treatment. <i>Diagnostics</i> , 2022, 12, 2068.	1.3	7
1020	Leveraging the Dynamic Immune Environment Triad in Patients with Breast Cancer: Tumour, Lymph Node, and Peripheral Blood. <i>Cancers</i> , 2022, 14, 4505.	1.7	4
1021	A vicious circle in breast cancer: The interplay between inflammation, reactive oxygen species, and microRNAs. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	8
1022	Myeloid-derived suppressor cells: an emerging target for anticancer immunotherapy. <i>Molecular Cancer</i> , 2022, 21, .	7.9	84
1024	Breast cancers co-opt normal mechanisms of tolerance to promote immune evasion and metastasis. <i>American Journal of Physiology - Cell Physiology</i> , 2022, 323, C1475-C1495.	2.1	6
1025	DCLK1 Suppresses Tumor-Specific Cytotoxic T Lymphocyte Function Through Recruitment of MDSCs via the CXCL1-CXCR2 Axis. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2023, 15, 463-485.	2.3	8
1026	Association of inflammatory markers with survival in patients with advanced gastric cancer treated with immune checkpoint inhibitors combined with chemotherapy as first line treatment. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	5
1027	Updates in combined approaches of radiotherapy and immune checkpoint inhibitors for the treatment of breast cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	6
1028	Antitumor effect of melatonin on breast cancer in experimental models: A systematic review. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2023, 1878, 188838.	3.3	9
1029	Aging tumour cells to cure cancer: "pro-senescence" therapy for cancer. <i>Swiss Medical Weekly</i> , 2017, 147, w14367.	0.8	22
1030	Immune landscape and immunotherapy for penile cancer. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
1031	Expression of Inhibitory Molecules (Arginase-1, IDO, and PD-L1) by Myeloid-Derived Suppressor Cells in Multiple Myeloma Patients in Remission. <i>Bulletin of Experimental Biology and Medicine</i> , 2022, 174, 71-75.	0.3	0
1032	Environmental exposure and the role of AhR in the tumor microenvironment of breast cancer. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	9
1033	Serum microRNAs as new criteria for referral to early palliative care services in treatment-naïve advanced cancer patients. <i>Oncotarget</i> , 2022, 13, 1341-1349.	0.8	0
1034	Role of myeloid-derived suppressor cells in tumor recurrence. <i>Cancer and Metastasis Reviews</i> , 2023, 42, 113-142.	2.7	7
1035	Cyclooxygenase-2-Prostaglandin E2 pathway: A key player in tumor-associated immune cells. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	23

#	ARTICLE	IF	CITATIONS
1036	Myeloid-Derived Suppressor Cells in Cancer and COVID-19 as Associated with Oxidative Stress. Vaccines, 2023, 11, 218.	2.1	4
1037	CAR T-cells to treat brain tumors. Brain Research Bulletin, 2023, 196, 76-98.	1.4	7
1038	Advances in chimeric antigen receptor T cells therapy in the treatment of breast cancer. Biomedicine and Pharmacotherapy, 2023, 162, 114609.	2.5	4
1039	POLD1 as a Prognostic Biomarker Correlated with Cell Proliferation and Immune Infiltration in Clear Cell Renal Cell Carcinoma. International Journal of Molecular Sciences, 2023, 24, 6849.	1.8	4
1040	Tumor-derived GCSF Alters Tumor and Systemic Immune System Cell Subset Composition and Signaling. Cancer Research Communications, 2023, 3, 404-419.	0.7	1
1041	Safety and efficacy of autologous cell vaccines in solid tumors: a systematic review and meta-analysis of randomized control trials. Scientific Reports, 2023, 13, .	1.6	6
1042	Immune Gene Therapy of Cancer. , 2023, , 1-45.		0
1043	Comprehensive analysis of nicotinamide metabolism-related signature for predicting prognosis and immunotherapy response in breast cancer. Frontiers in Immunology, 0, 14, .	2.2	1
1044	Inducible nitric oxide synthase-expressing myeloid-derived suppressor cells regulated by interleukin 35 contribute to the pathogenesis of psoriasis. Frontiers in Immunology, 0, 14, .	2.2	2
1045	Immune determinants of the pre-metastatic niche. Cancer Cell, 2023, 41, 546-572.	7.7	19
1046	Current Understanding of Flavonoids in Cancer Therapy and Prevention. Metabolites, 2023, 13, 481.	1.3	11
1047	The Metabolic Landscape of Breast Cancer and Its Therapeutic Implications. Molecular Diagnosis and Therapy, 0, , .	1.6	2
1050	Combining Cryo-Thermal Therapy with Anti-IL-6 Treatment Promoted the Maturation of MDSCs to Induce Long-Term Survival in a Mouse Model of Breast Cancer. International Journal of Molecular Sciences, 2023, 24, 7018.	1.8	0
1051	The regulation of the programmed death ligand 1 (PD-L1) by nitric oxide in breast cancer: Immunotherapeutic implication. , 2023, , 173-192.		0
1058	Current Clinical Landscape of Immunotherapeutic Approaches in Pancreatic Cancer Treatment. , 2023, , 327-380.		0
1068	Flow cytometric detection of CD11b+ Gr-1+ cells in nontumor-bearing mice: A propolis-elicited model. Methods in Cell Biology, 2023, , .	0.5	0
1069	CCL2â€“CCR2 Signaling Axis in Cancer. , 2023, , 241-270.		0
1074	Vitamin D and pancreatic cancer. , 2024, , 937-966.		0

#	ARTICLE	IF	CITATIONS
1079	In vitro generation of murine myeloid-derived suppressor cells from hematopoietic progenitor cells. <i>Methods in Cell Biology</i> , 2024, , 159-172.	0.5	0
1081	Myeloid-derived suppressor cells in cancer and cancer therapy. <i>Nature Reviews Clinical Oncology</i> , 2024, 21, 147-164.	12.5	1